{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T21:10:20Z","timestamp":1793913020383,"version":"4.8.0"},"reference-count":430,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T00:00:00Z","timestamp":1671148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>The endocannabinoid system has been shown to be involved in various skin functions, such as melanogenesis and the maintenance of redox balance in skin cells exposed to UV radiation, as well as barrier functions, sebaceous gland activity, wound healing and the skin\u2019s immune response. In addition to the potential use of cannabinoids in the treatment and prevention of skin cancer, cannabinoid compounds and derivatives are of interest as potential systemic and topical applications for the treatment of various inflammatory, fibrotic and pruritic skin conditions. In this context, cannabinoid compounds have been successfully tested as a therapeutic option for the treatment of androgenetic alopecia, atopic and seborrhoeic dermatitis, dermatomyositis, asteatotic and atopic eczema, uraemic pruritis, scalp psoriasis, systemic sclerosis and venous leg ulcers. This review provides an insight into the current literature on cannabinoid compounds as potential medicines for the treatment of skin diseases.<\/jats:p>","DOI":"10.3390\/cells11244102","type":"journal-article","created":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T07:27:30Z","timestamp":1671434850000},"page":"4102","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Cannabinoid Compounds as a Pharmacotherapeutic Option for the Treatment of Non-Cancer Skin Diseases"],"prefix":"10.3390","volume":"11","author":[{"given":"Robert","family":"Ramer","sequence":"first","affiliation":[{"name":"Institute of Pharmacology and Toxicology, Rostock University Medical Centre, Schillingallee 70, D-18057 Rostock, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2529-0732","authenticated-orcid":false,"given":"Burkhard","family":"Hinz","sequence":"additional","affiliation":[{"name":"Institute of Pharmacology and Toxicology, Rostock University Medical Centre, Schillingallee 70, D-18057 Rostock, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,12,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Ramer, R., Wendt, F., Wittig, F., Sch\u00e4fer, M., Boeckmann, L., Emmert, S., and Hinz, B. (2022). Impact of Cannabinoid Compounds on Skin Cancer. Cancers, 14.","DOI":"10.3390\/cancers14071769"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1177\/1203475418808761","article-title":"Dermatology-Related Uses of Medical Cannabis Promoted by Dispensaries in Canada, Europe, and the United States","volume":"23","author":"Lim","year":"2019","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1126\/science.1142265","article-title":"Attenuation of allergic contact dermatitis through the endocannabinoid system","volume":"316","author":"Karsak","year":"2007","journal-title":"Science"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"T\u00f3th, K.F., \u00c1d\u00e1m, D., B\u00edr\u00f3, T., and Ol\u00e1h, A. (2019). Cannabinoid Signaling in the Skin: Therapeutic Potential of the \u201cC(ut)annabinoid\u201d System. Molecules, 24.","DOI":"10.3390\/molecules24050918"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1159\/000455916","article-title":"The Inhibitory Effect of S-777469, a Cannabinoid Type 2 Receptor Agonist, on Skin Inflammation in Mice","volume":"99","author":"Haruna","year":"2017","journal-title":"Pharmacology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jdermsci.2006.10.009","article-title":"Cannabinoids inhibit human keratinocyte proliferation through a non-CB1\/CB2 mechanism and have a potential therapeutic value in the treatment of psoriasis","volume":"45","author":"Wilkinson","year":"2007","journal-title":"J. Dermatol. Sci."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Jarocka-Karpowicz, I., Biernacki, M., Wro\u0144ski, A., G\u0119gotek, A., and Skrzydlewska, E. (2020). Cannabidiol Effects on Phospholipid Metabolism in Keratinocytes from Patients with Psoriasis Vulgaris. Biomolecules, 10.","DOI":"10.3390\/biom10030367"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13075-021-02665-x","article-title":"Cannabinoid type 2 receptor (CB2R) distribution in dermatomyositis skin and peripheral blood mononuclear cells (PBMCs) and in vivo efects of LenabasumTM","volume":"24","author":"Maddukuri","year":"2022","journal-title":"Arthritis Res. Ther."},{"key":"ref_9","unstructured":"(2022, June 15). EU Designation Number: EU\/3\/18\/2070. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/orphan-designations\/eu3182070."},{"key":"ref_10","unstructured":"(2022, June 15). EU Designation Number: EU\/3\/16\/1808. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/orphan-designations\/eu3161808."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"121036","DOI":"10.1016\/j.ijpharm.2021.121036","article-title":"Development and optimisation of biopharmaceutical properties of a new microemulgel of cannabidiol for locally-acting dermatological delivery","volume":"607","author":"Vanti","year":"2021","journal-title":"Int. J. Pharm."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"21703","DOI":"10.1038\/srep21703","article-title":"The cannabinoid quinol VCE-004.8 alleviates bleomycin-induced scleroderma and exerts potent antifibrotic effects through peroxisome proliferator-activated receptor-\u03b3 and CB2 pathways","volume":"6","author":"Navarrete","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"16092","DOI":"10.1038\/s41598-018-34259-0","article-title":"VCE-004.8, A Multitarget Cannabinoquinone, Attenuates Adipogenesis and Prevents Diet-Induced Obesity","volume":"8","author":"Palomares","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.bcp.2018.07.047","article-title":"EHP-101, an oral formulation of the cannabidiol aminoquinone VCE-004.8, alleviates bleomycin-induced skin and lung fibrosis","volume":"157","author":"Navarrete","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.bcp.2019.02.029","article-title":"Cannabinoid derivatives acting as dual PPAR\u03b3\/CB2 agonists as therapeutic agents for systemic sclerosis","volume":"163","author":"Navarrete","year":"2019","journal-title":"Biochem. Pharmacol."},{"key":"ref_16","unstructured":"U.S. National Library of Medicine, ClinicalTrials.gov (2022, June 15). Study of the Safety, Tolerability and Efficacy of BTX 1204 in Patients with Moderate Atopic Dermatitis. ClinicalTrials.gov Identifier: NCT03824405, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03824405?term=CBD&cond=Skin+Diseases&draw=1&rank=15."},{"key":"ref_17","first-page":"208","article-title":"Use of a palmitoylethanolamide-containing nonsteroidal cream for treating atopic dermatitis: Impact on the duration of response and time between flares","volume":"20","year":"2007","journal-title":"Cosmetic Dermatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1111\/jocd.14263","article-title":"Novel cannabidiol aspartame combination treatment (JW-100) significantly reduces ISGA score in atopic dermatitis: Results from a randomized double-blinded placebo-controlled interventional study","volume":"21","author":"Gao","year":"2021","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1111\/bjd.17341","article-title":"Combined tetrahydrocannabinol and cannabidiol to treat pain in epidermolysis bullosa: A report of three cases","volume":"180","author":"Duipmans","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1186\/s13023-021-02010-0","article-title":"Cannabinoid use and effects in patients with epidermolysis bullosa: An international cross-sectional survey study","volume":"16","author":"Gorell","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.jpainsymman.2017.06.005","article-title":"Topical Medical Cannabis: A New Treatment for Wound Pain-Three Cases of Pyoderma Gangrenosum","volume":"54","author":"Maida","year":"2017","journal-title":"J. Pain Symptom Manag."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e224","DOI":"10.1111\/pde.13545","article-title":"Self-initiated use of topical cannabidiol oil for epidermolysis bullosa","volume":"35","author":"Chelliah","year":"2018","journal-title":"Pediatr. Dermatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1111\/j.1572-0241.2002.05852.x","article-title":"Preliminary observation with dronabinol in patients with intractable pruritus secondary to cholestatic liver disease","volume":"97","author":"Neff","year":"2002","journal-title":"Am. J. Gastroenterol."},{"key":"ref_24","first-page":"e23850","article-title":"Cutaneous Squamous Cell Carcinoma and Lichen Simplex Chronicus Successfully Treated with Topical Cannabinoid Oil: A Case Report and Summary of Cannabinoids in Dermatology","volume":"14","author":"Laborada","year":"2022","journal-title":"Cureus"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/BF00450585","article-title":"Toward drugs derived from cannabis","volume":"65","author":"Mechoulam","year":"1978","journal-title":"Naturwissenschaften"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/365061a0","article-title":"Molecular characterization of a peripheral receptor for cannabinoids","volume":"365","author":"Munro","year":"1993","journal-title":"Nature"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/346561a0","article-title":"Structure of a cannabinoid receptor and functional expression of the cloned cDNA","volume":"346","author":"Matsuda","year":"1990","journal-title":"Nature"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/sj.bjp.0707442","article-title":"The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: \u03949-tetrahydrocannabinol, cannabidiol and \u03949-tetrahydrocannabivarin","volume":"153","author":"Pertwee","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4790","DOI":"10.1111\/bph.13250","article-title":"Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor","volume":"172","author":"Laprairie","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0006-2952(95)00109-D","article-title":"Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors","volume":"50","author":"Mechoulam","year":"1995","journal-title":"Biochem. Pharmacol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1126\/science.1470919","article-title":"Isolation and structure of a brain constituent that binds to the cannabinoid receptor","volume":"258","author":"Devane","year":"1992","journal-title":"Science"},{"key":"ref_32","first-page":"498","article-title":"Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells","volume":"44","author":"Mackie","year":"1993","journal-title":"Mol. Pharmacol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1074\/jbc.274.5.2794","article-title":"Evidence that the cannabinoid CB1 receptor is a 2-arachidonoylglycerol receptor. Structure-activity relationship of 2-arachidonoylglycerol, ether-linked analogues, and related compounds","volume":"274","author":"Sugiura","year":"1999","journal-title":"J. Biol. Chem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1074\/jbc.275.1.605","article-title":"Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells","volume":"275","author":"Sugiura","year":"2000","journal-title":"J. Biol. Chem."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0306-9877(98)90198-0","article-title":"Fatty acid acylation of dopamine in the carotid body","volume":"50","author":"Pokorski","year":"1998","journal-title":"Med. Hypotheses"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1042\/bj3510817","article-title":"N-acyl-dopamines: Novel synthetic CB1 cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo","volume":"351","author":"Bisogno","year":"2000","journal-title":"Biochem. J."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"8400","DOI":"10.1073\/pnas.122196999","article-title":"An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors","volume":"99","author":"Huang","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1073\/pnas.061029898","article-title":"2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor","volume":"98","author":"Hanus","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1124\/jpet.301.3.1020","article-title":"Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor","volume":"301","author":"Porter","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"13717","DOI":"10.1038\/s41598-022-18266-w","article-title":"Pentadecanoylcarnitine is a newly discovered endocannabinoid with pleiotropic activities relevant to supporting physical and mental health","volume":"12","author":"Reiner","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1046\/j.1471-4159.2001.00092.x","article-title":"Gas chromatography-mass spectrometry analysis of endogenous cannabinoids in healthy and tumoral human brain and human cells in culture","volume":"76","author":"Maccarrone","year":"2001","journal-title":"J. Neurochem."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1080\/03602532.2018.1428344","article-title":"Targeting the endocannabinoid system as a potential anticancer approach","volume":"50","author":"Schwarz","year":"2018","journal-title":"Drug Metab. Rev."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1042\/bj3580249","article-title":"Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells","volume":"358","author":"Melck","year":"2001","journal-title":"Biochem. J."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1046\/j.1472-8206.2002.00094.x","article-title":"Effect on cancer cell proliferation of palmitoylethanolamide, a fatty acid amide interacting with both the cannabinoid and vanilloid signalling systems","volume":"16","author":"Bisogno","year":"2002","journal-title":"Fundam. Clin. Pharmacol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1042\/bj20020438","article-title":"Binding, degradation and apoptotic activity of stearoylethanolamide in rat C6 glioma cells","volume":"366","author":"Maccarrone","year":"2002","journal-title":"Biochem. J."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0014-2999(98)00392-6","article-title":"An entourage effect: Inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity","volume":"353","author":"Fride","year":"1998","journal-title":"Eur. J. Pharmacol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.phrs.2009.02.010","article-title":"The endocannabinoid system: Its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation","volume":"60","year":"2009","journal-title":"Pharmacol. Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/0006-2952(93)90486-G","article-title":"Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist","volume":"46","author":"Deutsch","year":"1993","journal-title":"Biochem. Pharmacol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.chembiol.2007.11.006","article-title":"A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol","volume":"14","author":"Blankman","year":"2007","journal-title":"Chem. Biol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"11082","DOI":"10.1074\/jbc.M413473200","article-title":"Molecular characterization of N-acylethanolamine-hydrolyzing acid amidase, a novel member of the choloylglycine hydrolase family with structural and functional similarity to acid ceramidase","volume":"280","author":"Tsuboi","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1021\/acschembio.5b00114","article-title":"A Potent Systemically Active N-Acylethanolamine Acid Amidase Inhibitor that Suppresses Inflammation and Human Macrophage Activation","volume":"10","author":"Ribeiro","year":"2015","journal-title":"ACS Chem. Biol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/22761","article-title":"Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide","volume":"400","author":"Zygmunt","year":"1999","journal-title":"Nature"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/sj.bjp.0704327","article-title":"Molecular targets for cannabidiol and its synthetic analogues: Effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide","volume":"134","author":"Bisogno","year":"2001","journal-title":"Br. J. Pharmacol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/sj.bjp.0705789","article-title":"Noladin ether, a putative endocannabinoid, attenuates sensory neurotransmission in the rat isolated mesenteric arterial bed via a non-CB1\/CB2 Gi\/o linked receptor","volume":"142","author":"Duncan","year":"2004","journal-title":"Br. J. Pharmacol."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Di Meo, C., Tortolani, D., Standoli, S., Angelucci, C.B., Fanti, F., Leuti, A., Sergi, M., Kadhim, S., Hsu, E., and Rapino, C. (2022). Effects of Rare Phytocannabinoids on the Endocannabinoid System of Human Keratinocytes. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23105430"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"6231","DOI":"10.1523\/JNEUROSCI.0504-08.2008","article-title":"TRPV2 is activated by cannabidiol and mediates CGRP release in cultured rat dorsal root ganglion neurons","volume":"28","author":"Qin","year":"2008","journal-title":"J. Neurosci."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1111\/j.1476-5381.2010.01166.x","article-title":"Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes","volume":"163","author":"Ligresti","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1748-1716.2011.02338.x","article-title":"Cannabinoid actions at TRPV channels: Effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation","volume":"204","author":"Orlando","year":"2012","journal-title":"Acta Physiol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1515\/jbcpp-2015-0080","article-title":"GPR55\u2014A putative \u201ctype 3\u201d cannabinoid receptor in inflammation","volume":"27","author":"Yang","year":"2016","journal-title":"J. Basic Clin. Physiol. Pharmacol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1038\/onc.2012.278","article-title":"The orphan receptor GPR55 drives skin carcinogenesis and is upregulated in human squamous cell carcinomas","volume":"32","author":"Andradas","year":"2013","journal-title":"Oncogene"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1038\/sj.bjp.0707460","article-title":"The orphan receptor GPR55 is a novel cannabinoid receptor","volume":"152","author":"Ryberg","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1073\/pnas.0711278105","article-title":"GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current","volume":"105","author":"Lauckner","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"29817","DOI":"10.1074\/jbc.M109.050187","article-title":"Atypical responsiveness of the orphan receptor GPR55 to cannabinoid ligands","volume":"284","author":"Kapur","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.cmet.2006.02.004","article-title":"Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents","volume":"3","author":"Overton","year":"2006","journal-title":"Cell Metab."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/mnfr.201500449","article-title":"G protein coupled receptor 18: A potential role for endocannabinoid signaling in metabolic dysfunction","volume":"60","author":"Rajaraman","year":"2016","journal-title":"Mol. Nutr. Food Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.bbrc.2006.06.175","article-title":"Identification of N-arachidonylglycine as the endogenous ligand for orphan G-protein-coupled receptor GPR18","volume":"347","author":"Kohno","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1124\/mol.108.045997","article-title":"N-palmitoyl glycine, a novel endogenous lipid that acts as a modulator of calcium influx and nitric oxide production in sensory neurons","volume":"74","author":"Rimmerman","year":"2008","journal-title":"Mol. Pharmacol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1111\/j.1476-5381.2011.01497.x","article-title":"\u03949-Tetrahydrocannabinol and N-arachidonyl glycine are full agonists at GPR18 receptors and induce migration in human endometrial HEC-1B cells","volume":"165","author":"McHugh","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1111\/bph.12746","article-title":"Activation of GPR18 by cannabinoid compounds: A tale of biased agonism","volume":"171","author":"Brailoiu","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Blunder, S., Pavel, P., Minzaghi, D., and Dubrac, S. (2021). PPARdelta in Affected Atopic Dermatitis and Psoriasis: A Possible Role in Metabolic Reprograming. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22147354"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/nature01921","article-title":"Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-\u03b1","volume":"425","author":"Fu","year":"2003","journal-title":"Nature"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1124\/mol.104.006353","article-title":"The nuclear receptor peroxisome proliferator-activated receptor-\u03b1 mediates the anti-inflammatory actions of palmitoylethanolamide","volume":"67","author":"Fu","year":"2005","journal-title":"Mol. Pharmacol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1002\/ptr.5601","article-title":"Palmitoylethanolamide Exerts Antiproliferative Effect and Downregulates VEGF Signaling in Caco-2 Human Colon Carcinoma Cell Line Through a Selective PPAR-\u03b1-Dependent Inhibition of Akt\/mTOR Pathway","volume":"30","author":"Sarnelli","year":"2016","journal-title":"Phytother. Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.tox.2014.09.011","article-title":"\u03949-THC modulation of fatty acid 2-hydroxylase (FA2H) gene expression: Possible involvement of induced levels of PPAR\u03b1 in MDA-MB-231 breast cancer cells","volume":"326","author":"Takeda","year":"2014","journal-title":"Toxicology"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/sj.bjp.0707478","article-title":"Cannabinoid activation of PPAR alpha; a novel neuroprotective mechanism","volume":"152","author":"Sun","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.bbrc.2005.09.121","article-title":"Novel time-dependent vascular actions of \u03949-tetrahydrocannabinol mediated by peroxisome proliferator-activated receptor gamma","volume":"337","author":"Tarling","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ejphar.2009.03.010","article-title":"Time-dependent vascular actions of cannabidiol in the rat aorta","volume":"612","author":"Sun","year":"2009","journal-title":"Eur. J. Pharmacol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/sj.bjp.0707423","article-title":"Cannabinoids go nuclear: Evidence for activation of peroxisome proliferator-activated receptors","volume":"152","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1124\/mol.63.5.983","article-title":"Activation and binding of peroxisome proliferator-activated receptor \u03b3 by synthetic cannabinoid ajulemic acid","volume":"63","author":"Liu","year":"2003","journal-title":"Mol. Pharmacol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"e618","DOI":"10.1038\/cddis.2013.141","article-title":"Involvement of PPAR\u03b3 in the antitumoral action of cannabinoids on hepatocellular carcinoma","volume":"4","author":"Vara","year":"2013","journal-title":"Cell Death Dis."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2131\/jts.45.227","article-title":"Cannabidiolic acid dampens the expression of cyclooxygenase-2 in MDA-MB-231 breast cancer cells: Possible implication of the peroxisome proliferator-activated receptor \u03b2\/\u03b4 abrogation","volume":"45","author":"Takeda","year":"2020","journal-title":"J. Toxicol. Sci."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.abb.2018.12.011","article-title":"\u03949-Tetrahydrocannabinol upregulates fatty acid 2-hydroxylase (FA2H) via PPAR\u03b1 induction: A possible evidence for the cancellation of PPAR\u03b2\/\u03b4-mediated inhibition of PPAR\u03b1 in MDA-MB-231 cells","volume":"662","author":"Takeda","year":"2019","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/0014-5793(96)00891-5","article-title":"Isolation and measurement of the endogenous cannabinoid receptor agonist, anandamide, in brain and peripheral tissues of human and rat","volume":"393","author":"Felder","year":"1996","journal-title":"FEBS Lett."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/28393","article-title":"Control of pain initiation by endogenous cannabinoids","volume":"394","author":"Calignano","year":"1998","journal-title":"Nature"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1038\/jid.2012.118","article-title":"Endocannabinoids regulate growth and survival of human eccrine sweat gland-derived epithelial cells","volume":"132","author":"Czifra","year":"2012","journal-title":"J. Investig. Dermatol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1096\/fj.06-7689com","article-title":"Inhibition of human hair follicle growth by endo- and exocannabinoids","volume":"21","author":"Telek","year":"2007","journal-title":"FASEB J."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jdermsci.2005.01.007","article-title":"Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skin","volume":"38","author":"Schmelz","year":"2005","journal-title":"J. Dermatol. Sci."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"3685","DOI":"10.1096\/fj.07-104877","article-title":"Endocannabinoids enhance lipid synthesis and apoptosis of human sebocytes via cannabinoid receptor-2-mediated signaling","volume":"22","author":"Dobrosi","year":"2008","journal-title":"FASEB J."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"15466","DOI":"10.1074\/jbc.M111.314880","article-title":"Endocannabinoids stimulate human melanogenesis via type-1 cannabinoid receptor","volume":"287","author":"Pucci","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"172462","DOI":"10.1016\/j.ejphar.2019.172462","article-title":"Evidence for TRPV4 channel induced skin vasodilatation through NOS, COX, and KCa channel mechanisms with no effect on sweat rate in humans","volume":"858","author":"Fujii","year":"2019","journal-title":"Eur. J. Pharmacol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1038\/jid.2011.122","article-title":"Activation of transient receptor potential vanilloid-3 inhibits human hair growth","volume":"131","author":"Lisztes","year":"2011","journal-title":"J. Investig. Dermatol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"316-e111","DOI":"10.1111\/vde.12658","article-title":"Cannabinoid receptor types 1 and 2 and peroxisome proliferator-activated receptor-\u03b1: Distribution in the skin of clinically healthy cats and cats with hypersensitivity dermatitis","volume":"29","author":"Miragliotta","year":"2018","journal-title":"Vet. Dermatol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1080\/000155500459240","article-title":"Expression of peroxisome proliferator activated receptors (PPARs) in human hair follicles and PPAR alpha involvement in hair growth","volume":"80","author":"Billoni","year":"2000","journal-title":"Acta Derm. Venereol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1046\/j.1523-1747.2001.01329.x","article-title":"Modulation of keratinocyte gene expression and differentiation by PPAR-selective ligands and tetradecylthioacetic acid","volume":"116","author":"Westergaard","year":"2001","journal-title":"J. Investig. Dermatol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.bbalip.2013.11.012","article-title":"Role of PPAR, LXR, and PXR in epidermal homeostasis and inflammation","volume":"1841","author":"Schmuth","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00109-005-0715-8","article-title":"Enzymes involved in the biosynthesis of leukotriene B4 and prostaglandin E2 are active in sebaceous glands","volume":"84","author":"Alestas","year":"2006","journal-title":"J. Mol. Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jdermsci.2016.10.005","article-title":"Sox9 facilitates proliferation, differentiation and lipogenesis in primary cultured human sebocytes","volume":"85","author":"Shi","year":"2017","journal-title":"J. Dermatol. Sci."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Wei, J., Ghosh, A.K., Sargent, J.L., Komura, K., Wu, M., Huang, Q.-Q., Jain, M., Whitfield, M.L., Feghali-Bostwick, C., and Varga, J. (2010). PPAR\u03b3 downregulation by TGF\u00df in fibroblast and impaired expression and function in systemic sclerosis: A novel mechanism for progressive fibrogenesis. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0013778"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/j.jid.2020.02.011","article-title":"GPR119 Is a Potent Regulator of Human Sebocyte Biology","volume":"140","author":"Markovics","year":"2020","journal-title":"J. Investig. Dermatol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.cbi.2017.06.005","article-title":"Cannabidiol upregulates melanogenesis through CB1 dependent pathway by activating p38 MAPK and p42\/44 MAPK","volume":"273","author":"Hwang","year":"2017","journal-title":"Chem. Biol. Interact."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00403-011-1126-z","article-title":"Inhibition of basal and ultraviolet B-induced melanogenesis by cannabinoid CB1 receptors: A keratinocyte-dependent effect","volume":"303","author":"Magina","year":"2011","journal-title":"Arch. Dermatol. Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3390\/jox12020012","article-title":"Comparative Study of \u03949-Tetrahydrocannabinol and Cannabidiol on Melanogenesis in Human Epidermal Melanocytes from Different Pigmentation Phototypes: A Pilot Study","volume":"12","author":"Goenka","year":"2022","journal-title":"J. Xenobiot."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/exd.14241","article-title":"The therapeutic potential of cannabinoids for integumentary wound management","volume":"30","author":"Weigelt","year":"2021","journal-title":"Exp. Dermatol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"120018","DOI":"10.1016\/j.lfs.2021.120018","article-title":"Genetic deletion of the cannabinoid receptors CB1 and CB2 enhances inflammation with diverging effects on skin wound healing in mice","volume":"285","author":"Ruhl","year":"2021","journal-title":"Life Sci."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12950-018-0201-z","article-title":"Cannabinoid 2 receptor attenuates inflammation during skin wound healing by inhibiting M1 macrophages rather than activating M2 macrophages","volume":"15","author":"Du","year":"2018","journal-title":"J. Inflamm."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ejphar.2016.06.006","article-title":"Pharmacological activation of cannabinoid 2 receptor attenuates inflammation, fibrogenesis, and promotes re-epithelialization during skin wound healing","volume":"786","author":"Wang","year":"2016","journal-title":"Eur. J. Pharmacol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.3892\/mmr.2016.4961","article-title":"Cannabinoid CB\u2082 receptors are involved in the regulation of fibrogenesis during skin wound repair in mice","volume":"13","author":"Li","year":"2016","journal-title":"Mol. Med. Rep."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"5306","DOI":"10.1039\/D0BM00338G","article-title":"Injectable postoperative enzyme-responsive hydrogels for reversing temozolomide resistance and reducing local recurrence after glioma operation","volume":"8","author":"Zhao","year":"2020","journal-title":"Biomater. Sci."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1177\/08853282211012870","article-title":"An enzyme-responsive Gp1a-hydrogel for skin wound healing","volume":"36","author":"Zhao","year":"2021","journal-title":"J. Biomater. Appl."},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Koyama, S., Purk, A., Kaur, M., Soini, H.A., Novotny, M.V., Davis, K., Kao, C.C., Matsunami, H., and Mescher, A. (2019). Beta-caryophyllene enhances wound healing through multiple routes. PLoS ONE, 14.","DOI":"10.1101\/611046"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.7717\/peerj.40","article-title":"A novel control of human keratin expression: Cannabinoid receptor 1-mediated signaling down-regulates the expression of keratins K6 and K16 in human keratinocytes in vitro and in situ","volume":"1","author":"Ramot","year":"2013","journal-title":"PeerJ"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"871","DOI":"10.3389\/fphar.2018.00871","article-title":"Topical Application of Adelmidrol + Trans-Traumatic Acid Enhances Skin Wound Healing in a Streptozotocin-Induced Diabetic Mouse Model","volume":"9","author":"Siracusa","year":"2018","journal-title":"Front. Pharmacol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.bcp.2016.09.001","article-title":"Adelmidrol, a palmitoylethanolamide analogue, as a new pharmacological treatment for the management of acute and chronic inflammation","volume":"119","author":"Impellizzeri","year":"2016","journal-title":"Biochem. Pharmacol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"E4397","DOI":"10.1073\/pnas.1605578113","article-title":"Endogenous N-acyl taurines regulate skin wound healing","volume":"113","author":"Sasso","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"105984","DOI":"10.18632\/oncotarget.22517","article-title":"Decisive role of P42\/44 mitogen-activated protein kinase in \u03949-tetrahydrocannabinol-induced migration of human mesenchymal stem cells","volume":"8","author":"Ramer","year":"2017","journal-title":"Oncotarget"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.bcp.2013.11.016","article-title":"Increase of mesenchymal stem cell migration by cannabidiol via activation of p42\/44 MAPK","volume":"87","author":"Schmuhl","year":"2014","journal-title":"Biochem. Pharmacol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1194\/jlr.M061473","article-title":"Inhibition of FAAH confers increased stem cell migration via PPAR\u03b1","volume":"56","author":"Wollank","year":"2015","journal-title":"J. Lipid Res."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"862391","DOI":"10.1155\/2015\/862391","article-title":"Flax Fiber Hydrophobic Extract Inhibits Human Skin Cells Inflammation and Causes Remodeling of Extracellular Matrix and Wound Closure Activation","volume":"2015","author":"Styrczewska","year":"2015","journal-title":"Biomed Res. Int."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"8063","DOI":"10.3390\/ijms15058063","article-title":"CB2 receptor activation inhibits melanoma cell transmigration through the blood-brain barrier","volume":"15","author":"Fazakas","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"ref_120","first-page":"1178","article-title":"Standardized Cannabis sativa extract attenuates tau and stathmin gene expression in the melanoma cell line","volume":"20","author":"Vaseghi","year":"2017","journal-title":"Iran. J. Basic Med. Sci."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"549","DOI":"10.4103\/0973-1482.106534","article-title":"Cannabinoid receptor 2 is upregulated in melanoma","volume":"8","author":"Zhao","year":"2012","journal-title":"J. Cancer Res. Ther."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"272","DOI":"10.18632\/oncoscience.33","article-title":"Regulation of circulating endocannabinoids associated with cancer and metastases in mice and humans","volume":"1","author":"Sailler","year":"2014","journal-title":"Oncoscience"},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Hohmann, U., Walsleben, C., Ghadban, C., Kirchhoff, F., Dehghani, F., and Hohmann, T. (2022). Interaction of Glia Cells with Glioblastoma and Melanoma Cells under the Influence of Phytocannabinoids. Cells, 11.","DOI":"10.3390\/cells11010147"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.tiv.2017.01.018","article-title":"Tumor-promoting effects of cannabinoid receptor type 1 in human melanoma cells","volume":"40","author":"Carpi","year":"2017","journal-title":"Toxicol. Vitro"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"112560","DOI":"10.1016\/j.msec.2021.112560","article-title":"A cannabidiol-containing alginate based hydrogel as novel multifunctional wound dressing for promoting wound healing","volume":"134","author":"Zheng","year":"2022","journal-title":"Biomater. Adv."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1111\/exd.14395","article-title":"Topical cannabis-based medicines\u2014A novel adjuvant treatment for venous leg ulcers: An open-label trial","volume":"30","author":"Maida","year":"2021","journal-title":"Exp. Dermatol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/j.1600-0625.2012.01561.x","article-title":"Cannabinoid receptors 1 and 2 oppositely regulate epidermal permeability barrier status and differentiation","volume":"21","author":"Roelandt","year":"2012","journal-title":"Exp. Dermatol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"e401","DOI":"10.1111\/ijd.12841","article-title":"Topical cannabinoid receptor 1 agonist attenuates the cutaneous inflammatory responses in oxazolone-induced atopic dermatitis model","volume":"54","author":"Kim","year":"2015","journal-title":"Int. J. Dermatol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1111\/exd.14012","article-title":"Modulators of the endocannabinoid system influence skin barrier repair, epidermal proliferation, differentiation and inflammation in a mouse model","volume":"28","author":"Proksch","year":"2019","journal-title":"Exp. Dermatol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1600-0536.2009.01656.x","article-title":"Interlaboratory studies with a proposed patch test design to evaluate the irritation potential of surfactants","volume":"62","author":"Mehling","year":"2010","journal-title":"Contact Dermat."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1128\/AAC.01308-07","article-title":"Mouse beta-defensin-14, an antimicrobial ortholog of human beta-defensin-3","volume":"52","author":"Hinrichsen","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Shin, K.-O., Kim, S., Park, B.D., Uchida, Y., and Park, K. (2021). N-Palmitoyl Serinol Stimulates Ceramide Production through a CB1-Dependent Mechanism in In Vitro Model of Skin Inflammation. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22158302"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1124\/mol.64.5.1189","article-title":"Ceramide is involved in R(+)-methanandamide-induced cyclooxygenase-2 expression in human neuroglioma cells","volume":"64","author":"Ramer","year":"2003","journal-title":"Mol. Pharmacol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/73171","article-title":"Anti-tumoral action of cannabinoids: Involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation","volume":"6","author":"Izquierdo","year":"2000","journal-title":"Nat. Med."},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Ikarashi, N., Shiseki, M., Yoshida, R., Tabata, K., Kimura, R., Watanabe, T., Kon, R., Sakai, H., and Kamei, J. (2021). Cannabidiol Application Increases Cutaneous Aquaporin-3 and Exerts a Skin Moisturizing Effect. Pharmaceuticals, 14.","DOI":"10.3390\/ph14090879"},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Konger, R.L., Derr-Yellin, E., Zimmers, T.A., Katona, T., Xuei, X., Liu, Y., Zhou, H.-M., Simpson, E.R., and Turner, M.J. (2021). Epidermal PPAR\u03b3 Is a Key Homeostatic Regulator of Cutaneous Inflammation and Barrier Function in Mouse Skin. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22168634"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1083\/jcb.200605057","article-title":"Lipid defect underlies selective skin barrier impairment of an epidermal-specific deletion of Gata-3","volume":"175","author":"Wertz","year":"2006","journal-title":"J. Cell Biol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"72","DOI":"10.4161\/derm.1.2.7811","article-title":"Epidermal surface lipids","volume":"1","author":"Pappas","year":"2009","journal-title":"Dermatoendocrinology"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.imbio.2017.10.047","article-title":"Protective role of peroxisome proliferator-activated receptor \u03b1 agonists in skin barrier and inflammation","volume":"223","author":"Furue","year":"2018","journal-title":"Immunobiology"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1016\/j.jid.2018.02.022","article-title":"Endocannabinoid Tone Regulates Human Sebocyte Biology","volume":"138","author":"Markovics","year":"2018","journal-title":"J. Investig. Dermatol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s00424-011-0941-6","article-title":"\u201cSebocytes\u2019 makeup\u201d: Novel mechanisms and concepts in the physiology of the human sebaceous glands","volume":"461","author":"Czifra","year":"2011","journal-title":"Pflugers Arch."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1038\/sj.jid.5700336","article-title":"Peroxisome proliferator-activated receptors increase human sebum production","volume":"126","author":"Trivedi","year":"2006","journal-title":"J. Investig. Dermatol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/j.1365-2133.2010.10037.x","article-title":"Peroxisome proliferator-activated receptor activators protect sebocytes from apoptosis: A new treatment modality for acne?","volume":"164","author":"Schuster","year":"2011","journal-title":"Br. J. Dermatol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.jid.2017.09.024","article-title":"Delayed Hair Follicle Morphogenesis and Hair Follicle Dystrophy in a Lipoatrophy Mouse Model of Pparg Total Deletion","volume":"138","author":"Sardella","year":"2018","journal-title":"J. Investig. Dermatol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jid.2018.07.015","article-title":"Activation of TRPV3 Inhibits Lipogenesis and Stimulates Production of Inflammatory Mediators in Human Sebocytes-A Putative Contributor to Dry Skin Dermatoses","volume":"139","author":"Zouboulis","year":"2019","journal-title":"J. Investig. Dermatol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.jid.2017.07.852","article-title":"Activation of TRPV3 Regulates Inflammatory Actions of Human Epidermal Keratinocytes","volume":"138","author":"Vasas","year":"2018","journal-title":"J. Investig. Dermatol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1159\/000512189","article-title":"A Review of the Current Evidence Connecting Seborrheic Dermatitis and Parkinson\u2019s Disease and the Potential Role of Oral Cannabinoids","volume":"237","author":"Rietcheck","year":"2020","journal-title":"Dermatology"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/exd.14294","article-title":"Human epithelial stem cell survival within their niche requires \u201ctonic\u201d cannabinoid receptor 1-signalling-Lessons from the hair follicle","volume":"30","author":"Sugawara","year":"2021","journal-title":"Exp. Dermatol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1038\/jid.2008.369","article-title":"Hair follicle stem cell-specific PPAR\u03b3 deletion causes scarring alopecia","volume":"129","author":"Karnik","year":"2009","journal-title":"J. Investig. Dermatol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1111\/j.1742-4658.2005.04690.x","article-title":"Biogenesis of peroxisomes. Topogenesis of the peroxisomal membrane and matrix proteins","volume":"272","author":"Heiland","year":"2005","journal-title":"FEBS J."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"3992","DOI":"10.1158\/0008-5472.CAN-07-6594","article-title":"The cannabinoid receptors are required for ultraviolet-induced inflammation and skin cancer development","volume":"68","author":"Zheng","year":"2008","journal-title":"Cancer Res."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"113656","DOI":"10.1016\/j.jpba.2020.113656","article-title":"Therapeutic application of cannabidiol on UVA and UVB irradiated rat skin. A proteomic study","volume":"192","author":"Atalay","year":"2021","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_153","doi-asserted-by":"crossref","unstructured":"Jastrz\u0105b, A., G\u0119gotek, A., and Skrzydlewska, E. (2019). Cannabidiol Regulates the Expression of Keratinocyte Proteins Involved in the Inflammation Process through Transcriptional Regulation. Cells, 8.","DOI":"10.3390\/cells8080827"},{"key":"ref_154","doi-asserted-by":"crossref","unstructured":"Perez, E., Fernandez, J.R., Fitzgerald, C., Rouzard, K., Tamura, M., and Savile, C. (2022). In Vitro and Clinical Evaluation of Cannabigerol (CBG) Produced via Yeast Biosynthesis: A Cannabinoid with a Broad Range of Anti-Inflammatory and Skin Health-Boosting Properties. Molecules, 27.","DOI":"10.3390\/molecules27020491"},{"key":"ref_155","first-page":"11","article-title":"The expression of cannabinoid-related genes in multiple disease cell lines","volume":"8","author":"Arlen","year":"2020","journal-title":"Appl. Cell Biol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1369\/0022155420938031","article-title":"The Mast Cell-SCF-CB1 Interaction Is a Key Player in Seborrheic Keratosis","volume":"68","author":"Sugawara","year":"2020","journal-title":"J. Histochem. Cytochem."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1590\/S0365-05962012000300012","article-title":"Actinic keratosis: A clinical and epidemiological revision","volume":"87","author":"Schmitt","year":"2012","journal-title":"An. Bras. Dermatol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.jaci.2011.11.009","article-title":"Endocannabinoids limit excessive mast cell maturation and activation in human skin","volume":"129","author":"Sugawara","year":"2012","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s13555-020-00425-4","article-title":"Management Pearls on the Treatment of Actinic Keratoses and Field Cancerization","volume":"10","author":"Gilaberte","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1002\/bies.201400006","article-title":"Harnessing neuroendocrine controls of keratin expression: A new therapeutic strategy for skin diseases?","volume":"36","author":"Ramot","year":"2014","journal-title":"Bioessays"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"101321","DOI":"10.1016\/j.redox.2019.101321","article-title":"Cannabidiol induces antioxidant pathways in keratinocytes by targeting BACH1","volume":"28","author":"Casares","year":"2020","journal-title":"Redox Biol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/bph.12309","article-title":"Epigenetic control of skin differentiation genes by phytocannabinoids","volume":"170","author":"Pucci","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"6005","DOI":"10.1074\/jbc.M707964200","article-title":"Anandamide regulates keratinocyte differentiation by inducing DNA methylation in a CB1 receptor-dependent manner","volume":"283","author":"Paradisi","year":"2008","journal-title":"J. Biol. Chem."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"33896","DOI":"10.1074\/jbc.M303994200","article-title":"The endocannabinoid system in human keratinocytes. Evidence that anandamide inhibits epidermal differentiation through CB1 receptor-dependent inhibition of protein kinase C, activation protein-1, and transglutaminase","volume":"278","author":"Maccarrone","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"200.e11","DOI":"10.1016\/j.neurobiolaging.2010.07.009","article-title":"Early onset of aging-like changes is restricted to cognitive abilities and skin structure in Cnr1\u207b\/\u207b mice","volume":"33","author":"Drews","year":"2012","journal-title":"Neurobiol. Aging"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"111528","DOI":"10.1016\/j.exger.2021.111528","article-title":"Diabetes and Cannabinoid CB1 receptor deficiency promote similar early onset aging-like changes in the skin","volume":"154","author":"Leal","year":"2021","journal-title":"Exp. Gerontol."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/exd.14110","article-title":"Mitochondrial energy metabolism is negatively regulated by cannabinoid receptor 1 in intact human epidermis","volume":"29","author":"Alam","year":"2020","journal-title":"Exp. Dermatol."},{"key":"ref_168","doi-asserted-by":"crossref","unstructured":"Zag\u00f3rska-Dziok, M., Bujak, T., Ziemlewska, A., and Nizio\u0142-\u0141ukaszewska, Z. (2021). Positive Effect of Cannabis sativa L. Herb Extracts on Skin Cells and Assessment of Cannabinoid-Based Hydrogels Properties. Molecules, 26.","DOI":"10.3390\/molecules26040802"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"744857","DOI":"10.3389\/fendo.2021.744857","article-title":"Peripheral Hybrid CB1R and iNOS Antagonist MRI-1867 Displays Anti-Fibrotic Efficacy in Bleomycin-Induced Skin Fibrosis","volume":"12","author":"Zawatsky","year":"2021","journal-title":"Front. Endocrinol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"18488","DOI":"10.1074\/jbc.M413260200","article-title":"Evidence for the involvement of the cannabinoid CB2 receptor and its endogenous ligand 2-arachidonoylglycerol in 12-O-tetradecanoylphorbol-13-acetate-induced acute inflammation in mouse ear","volume":"280","author":"Oka","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"8796","DOI":"10.4049\/jimmunol.177.12.8796","article-title":"Involvement of the cannabinoid CB2 receptor and its endogenous ligand 2-arachidonoylglycerol in oxazolone-induced contact dermatitis in mice","volume":"177","author":"Oka","year":"2006","journal-title":"J. Immunol."},{"key":"ref_172","doi-asserted-by":"crossref","unstructured":"Ambro\u017cewicz, E., W\u00f3jcik, P., Wro\u0144ski, A., \u0141uczaj, W., Jastrz\u0105b, A., \u017darkovi\u0107, N., and Skrzydlewska, E. (2018). Pathophysiological Alterations of Redox Signaling and Endocannabinoid System in Granulocytes and Plasma of Psoriatic Patients. Cells, 7.","DOI":"10.3390\/cells7100159"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.jid.2017.12.029","article-title":"The Genetics of Chronic Itch: Gene Expression in the Skin of Patients with Atopic Dermatitis and Psoriasis with Severe Itch","volume":"138","author":"Nattkemper","year":"2018","journal-title":"J. Investig. Dermatol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"988","DOI":"10.2460\/ajvr.73.7.988","article-title":"Cannabinoid receptor type 1 and 2 expression in the skin of healthy dogs and dogs with atopic dermatitis","volume":"73","author":"Campora","year":"2012","journal-title":"Am. J. Vet. Res."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s00414-012-0741-3","article-title":"Cannabinoid receptor type 2 is time-dependently expressed during skin wound healing in mice","volume":"126","author":"Zheng","year":"2012","journal-title":"Int. J. Legal Med."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"173738","DOI":"10.1016\/j.ejphar.2020.173738","article-title":"AM251, a cannabinoid receptor 1 antagonist, prevents human fibroblasts differentiation and collagen deposition induced by TGF-\u03b2\u2014An in vitro study","volume":"892","author":"Carvalho","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/fcp.12716","article-title":"Targeting cannabinoid receptor 2 (CB2) limits collagen production-An in vitro study in a primary culture of human fibroblasts","volume":"36","author":"Carvalho","year":"2022","journal-title":"Fundam. Clin. Pharmacol."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"790712","DOI":"10.3389\/fphar.2022.790712","article-title":"CB2R Deficiency Exacerbates Imiquimod-Induced Psoriasiform Dermatitis and Itch Through the Neuro-Immune Pathway","volume":"13","author":"Li","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1038\/jid.2011.424","article-title":"Distribution and expression of non-neuronal transient receptor potential (TRPV) ion channels in rosacea","volume":"132","author":"Sulk","year":"2012","journal-title":"J. Investig. Dermatol."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.jaci.2017.05.051","article-title":"Transient receptor potential vanilloid 4-expressing macrophages and keratinocytes contribute differentially to allergic and nonallergic chronic itch","volume":"141","author":"Luo","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/j.0303-6987.2005.00345.x","article-title":"Peroxisome proliferator-activated receptors in squamous cell carcinoma and its precursors","volume":"32","author":"Nijsten","year":"2005","journal-title":"J. Cutan. Pathol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.jaci.2007.12.1165","article-title":"Peroxisome proliferator-activated receptor alpha regulates skin inflammation and humoral response in atopic dermatitis","volume":"121","author":"Abboud","year":"2008","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1111\/j.1468-3083.2011.04337.x","article-title":"Defective barrier function in melasma skin","volume":"26","author":"Lee","year":"2012","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1136\/annrheumdis-2015-208029","article-title":"Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis","volume":"75","author":"Ruzehaji","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jdermsci.2009.10.008","article-title":"UV decreases the synthesis of free fatty acids and triglycerides in the epidermis of human skin in vivo, contributing to development of skin photoaging","volume":"57","author":"Kim","year":"2010","journal-title":"J. Dermatol. Sci."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"107","DOI":"10.7241\/ourd.20142.27","article-title":"Estimation of peroxisome proliferators\u2014Activated receptor \u03b3 gene expression in inflammatory skin diseases: Atopic dermatitis and psoriasis","volume":"5","author":"Mahgoub","year":"2014","journal-title":"Our Dermatol. Online"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"579372","DOI":"10.3389\/fimmu.2020.579372","article-title":"Increased Expression of PPAR-\u03b3 Modulates Monocytes Into a M2-Like Phenotype in SLE Patients: An Implicative Protective Mechanism and Potential Therapeutic Strategy of Systemic Lupus Erythematosus","volume":"11","author":"Liu","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1046\/j.1523-1747.2003.12536.x","article-title":"Expression and localization of peroxisome proliferator-activated receptors and nuclear factor \u03baB in normal and lesional psoriatic skin","volume":"121","author":"Westergaard","year":"2003","journal-title":"J. Investig. Dermatol."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/ejp.1654","article-title":"Psoralens activate and photosensitize Transient Receptor Potential channels Ankyrin type 1 (TRPA1) and Vanilloid type 1 (TRPV1)","volume":"25","author":"Babes","year":"2021","journal-title":"Eur. J. Pain"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"e15162","DOI":"10.1111\/dth.15162","article-title":"Cannabinoids interaction with transient receptor potential family and implications in the treatment of rosacea","volume":"34","author":"Smith","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1038\/jid.2011.87","article-title":"Antipruritic effects of TRPV1 antagonist in murine atopic dermatitis and itching models","volume":"131","author":"Yun","year":"2011","journal-title":"J. Investig. Dermatol."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/sj.jid.5700590","article-title":"Effects of skin surface temperature on epidermal permeability barrier homeostasis","volume":"127","author":"Denda","year":"2007","journal-title":"J. Investig. Dermatol."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"772941","DOI":"10.3389\/fimmu.2021.772941","article-title":"Cutaneous Neuroimmune Interactions of TSLP and TRPV4 Play Pivotal Roles in Dry Skin-Induced Pruritus","volume":"12","author":"Lee","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1080\/00016489.2017.1336796","article-title":"Expressions of TRPVs in the cholesteatoma epithelium","volume":"137","author":"Do","year":"2017","journal-title":"Acta Otolaryngol."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"e94463","DOI":"10.1172\/jci.insight.94463","article-title":"Pro-resolving mediators promote resolution in a human skin model of UV-killed Escherichia coli-driven acute inflammation","volume":"3","author":"Motwani","year":"2018","journal-title":"JCI Insight"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/ced.12394","article-title":"The Pro12Ala polymorphism of the gene for peroxisome proliferator activated receptor-gamma is associated with a lower Global Acne Grading System score in patients with acne vulgaris","volume":"39","author":"Amr","year":"2014","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"256","DOI":"10.4168\/aair.2015.7.3.256","article-title":"Antiallergic Function of KR62980, a Peroxisome Proliferator-Activated Receptor-\u03b3 Agonist, in a Mouse Allergic Rhinitis Model","volume":"7","author":"Lee","year":"2015","journal-title":"Allergy Asthma Immunol. Res."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1159\/000508989","article-title":"The Role of Cannabinoids in Allergic Diseases: Collegium Internationale Allergologicum (CIA) Update 2020","volume":"181","author":"Angelina","year":"2020","journal-title":"Int. Arch. Allergy Immunol."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1002\/cbdv.200790144","article-title":"History of cannabis and its preparations in saga, science, and sobriquet","volume":"4","author":"Russo","year":"2007","journal-title":"Chem. Biodivers."},{"key":"ref_200","doi-asserted-by":"crossref","unstructured":"Pertwee, R.G. (2014). The Pharmacological History of Cannabis. Handbook of Cannabis, Oxford University Press. [1st ed.].","DOI":"10.1093\/acprof:oso\/9780199662685.001.0001"},{"key":"ref_201","unstructured":"Lemery, N. (1727). Dictionaire ou Traite Universel Des Drogues Simples, Jean Hofhout."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.pain.2004.02.020","article-title":"Activation of peripheral cannabinoid receptors attenuates cutaneous hyperalgesia produced by a heat injury","volume":"109","author":"Johanek","year":"2004","journal-title":"Pain"},{"key":"ref_203","first-page":"646","article-title":"Anti-edema and analgesic properties of \u03949-tetrahydrocannabinol (THC)","volume":"186","author":"Sofia","year":"1973","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/0024-3205(74)90214-8","article-title":"Comparative anti-phlogistic activity of \u03949-tetrahydrocannabinol, hydrocortisone and aspirin in various rat paw edema models","volume":"15","author":"Nalepa","year":"1974","journal-title":"Life Sci."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0304-3959(02)00450-5","article-title":"A cannabinoid agonist differentially attenuates deep tissue hyperalgesia in animal models of cancer and inflammatory muscle pain","volume":"103","author":"Kehl","year":"2003","journal-title":"Pain"},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0304-3959(01)00454-7","article-title":"CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain","volume":"96","author":"Clayton","year":"2002","journal-title":"Pain"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"14228","DOI":"10.1073\/pnas.96.25.14228","article-title":"HU-308: A specific agonist for CB2, a peripheral cannabinoid receptor","volume":"96","author":"Hanus","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"5577","DOI":"10.1021\/ja01577a066","article-title":"The identification of N-(2-hydroxyethyl)-palmitamide as a naturally occurring anti-inflammatory agent","volume":"79","author":"Kuehl","year":"1957","journal-title":"J. Am. Chem. Soc."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/sj.bjp.0704900","article-title":"Therapeutic effect of the endogenous fatty acid amide, palmitoylethanolamide, in rat acute inflammation: Inhibition of nitric oxide and cyclo-oxygenase systems","volume":"137","author":"Costa","year":"2002","journal-title":"Br. J. Pharmacol."},{"key":"ref_210","first-page":"809","article-title":"Attivita\u2019 di alcuni derivati della palmitoiletanolamide sull\u2019edema da carragenina nella zampa di ratto [Activity of some derivatives of palmitoylethanolamide on carragenine-induced edema in the rat paw]","volume":"44","author":"Benvenuti","year":"1968","journal-title":"Boll. Soc. Ital. Biol. Sper."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/0014-2999(96)00015-5","article-title":"N-(2-Hydroxyethyl)hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation","volume":"300","author":"Mazzari","year":"1996","journal-title":"Eur. J. Pharmacol."},{"key":"ref_212","first-page":"99","article-title":"Palmitoylethanolamide versus a nonsteroidal anti-inflammatory drug in the treatment of temporomandibular joint inflammatory pain","volume":"26","author":"Marini","year":"2012","journal-title":"J. Orofac. Pain"},{"key":"ref_213","first-page":"353","article-title":"Efficacy of Palmitoylethanolamide for Pain: A Meta-Analysis","volume":"20","author":"Artukoglu","year":"2017","journal-title":"Pain Physician"},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1007\/s11481-015-9611-3","article-title":"A CB2-Selective Cannabinoid Suppresses T-Cell Activities and Increases Tregs and IL-10","volume":"10","author":"Robinson","year":"2015","journal-title":"J. Neuroimmune Pharmacol."},{"key":"ref_215","doi-asserted-by":"crossref","unstructured":"Ke, P., Shao, B.-Z., Xu, Z.-Q., Wei, W., Han, B.-Z., Chen, X.-W., Su, D.-F., and Liu, C. (2016). Activation of Cannabinoid Receptor 2 Ameliorates DSS-Induced Colitis through Inhibiting NLRP3 Inflammasome in Macrophages. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0155076"},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1124\/jpet.114.220368","article-title":"Protective role of cannabinoid receptor 2 activation in galactosamine\/lipopolysaccharide-induced acute liver failure through regulation of macrophage polarization and microRNAs","volume":"353","author":"Tomar","year":"2015","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0006-2952(02)01604-0","article-title":"Suppression of human monocyte interleukin-1\u03b2 production by ajulemic acid, a nonpsychoactive cannabinoid","volume":"65","author":"Zurier","year":"2003","journal-title":"Biochem. Pharmacol."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.neulet.2005.03.019","article-title":"Effect of the cannabinoid ajulemic acid on rat models of neuropathic and inflammatory pain","volume":"382","author":"Mitchell","year":"2005","journal-title":"Neurosci. Lett."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1136\/annrheumdis-2011-200314","article-title":"Synthetic cannabinoid ajulemic acid exerts potent antifibrotic effects in experimental models of systemic sclerosis","volume":"71","author":"Gonzalez","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s00296-007-0489-0","article-title":"Suppression of human macrophage interleukin-6 by a nonpsychoactive cannabinoid acid","volume":"28","author":"Parker","year":"2008","journal-title":"Rheumatol. Int."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/cpt.980","article-title":"Potent Anti-Inflammatory and Pro-Resolving Effects of Anabasum in a Human Model of Self-Resolving Acute Inflammation","volume":"104","author":"Motwani","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1124\/molpharm.120.000083","article-title":"Molecular Mechanisms for the Inflammation-Resolving Actions of Lenabasum","volume":"99","author":"Burstein","year":"2021","journal-title":"Mol. Pharmacol."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1084\/jem.20150225","article-title":"Identification of resolvin D2 receptor mediating resolution of infections and organ protection","volume":"212","author":"Chiang","year":"2015","journal-title":"J. Exp. Med."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1124\/jpet.108.150136","article-title":"Endocannabinoid modulation of scratching response in an acute allergenic model: A new prospective neural therapeutic target for pruritus","volume":"329","author":"Schlosburg","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_225","first-page":"473","article-title":"Role of Nitric Oxide in the Antipruritic Effect of WIN 55,212-2, a Cannabinoid Agonist","volume":"11","author":"Gercek","year":"2020","journal-title":"Basic Clin. Neurosci."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1016\/j.bmcl.2012.02.072","article-title":"Discovery of S-777469: An orally available CB2 agonist as an antipruritic agent","volume":"22","author":"Odan","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1159\/000371890","article-title":"S-777469, a novel cannabinoid type 2 receptor agonist, suppresses itch-associated scratching behavior in rodents through inhibition of itch signal transmission","volume":"95","author":"Haruna","year":"2015","journal-title":"Pharmacology"},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s00403-019-01963-4","article-title":"Double blinded, vehicle controlled, crossover study on the efficacy of a topical endocannabinoid membrane transporter inhibitor in atopic Beagles","volume":"311","author":"Marsella","year":"2019","journal-title":"Arch. Dermatol. Res."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jmpt.2013.05.018","article-title":"Itch sensation through transient receptor potential channels: A systematic review and relevance to manual therapy","volume":"36","author":"Lucaciu","year":"2013","journal-title":"J. Manip. Physiol. Ther."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1111\/bph.15733","article-title":"Glucosylsphingosine evokes pruritus via activation of 5-HT2A receptor and TRPV4 in sensory neurons","volume":"179","author":"Sanjel","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"102429","DOI":"10.1016\/j.ceca.2021.102429","article-title":"Cimifugin relieves pruritus in psoriasis by inhibiting TRPV4","volume":"97","author":"Yan","year":"2021","journal-title":"Cell Calcium"},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.jid.2019.07.690","article-title":"The Phytocannabinoid (-)-Cannabidiol Operates as a Complex, Differential Modulator of Human Hair Growth: Anti-Inflammatory Submicromolar versus Hair Growth Inhibitory Micromolar Effects","volume":"140","author":"Lisztes","year":"2020","journal-title":"J. Investig. Dermatol."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/S0190-9622(84)80498-3","article-title":"The inheritance of common baldness: Two B or not two B?","volume":"11","author":"Happle","year":"1984","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_234","unstructured":"Thiers, B.H., and Dobson, R.L. (1986). Pathogenesis of Skin Disease, Churchill Livingstone."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/aja.1000710306","article-title":"Male hormone stimulation is prerequisite and an incitant in common baldness","volume":"71","author":"Hamilton","year":"1942","journal-title":"Am. J. Anat."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1111\/j.1749-6632.1951.tb31971.x","article-title":"Patterned loss of hair in man; types and incidence","volume":"53","author":"Hamilton","year":"1951","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1111\/jdv.15081","article-title":"Efficacy of non-surgical treatments for androgenetic alopecia: A systematic review and network meta-analysis","volume":"32","author":"Gupta","year":"2018","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1080\/14740338.2018.1430765","article-title":"Androgenetic alopecia; drug safety and therapeutic strategies","volume":"17","author":"Motofei","year":"2018","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_239","doi-asserted-by":"crossref","unstructured":"Gentile, P., and Garcovich, S. (2020). Systematic Review of Platelet-Rich Plasma Use in Androgenetic Alopecia Compared with Minoxidil\u00ae, Finasteride\u00ae, and Adult Stem Cell-Based Therapy. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21082702"},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/0190-9622(93)70106-4","article-title":"Diagnostic and predictive value of horizontal sections of scalp biopsy specimens in male pattern androgenetic alopecia","volume":"28","author":"Whiting","year":"1993","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"73","DOI":"10.4103\/0974-7753.122963","article-title":"Evaluation of Perifollicular Inflammation of Donor Area during Hair Transplantation in Androgenetic Alopecia and its Comparison with Controls","volume":"5","author":"Nirmal","year":"2013","journal-title":"Int. J. Trichology"},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1111\/jocd.14352","article-title":"Cannabinoids for skin diseases and hair regrowth","volume":"20","author":"Gupta","year":"2021","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"68","DOI":"10.3831\/KPI.2021.24.2.68","article-title":"Regulatory Effect of Cannabidiol (CBD) on Decreased \u03b2-Catenin Expression in Alopecia Models by Testosterone and PMA Treatment in Dermal Papilla Cells","volume":"24","author":"Park","year":"2021","journal-title":"J. Pharmacopunct."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1016\/j.bmcl.2009.03.046","article-title":"Hair growth stimulator property of thienyl substituted pyrazole carboxamide derivatives as a CB1 receptor antagonist with in vivo antiobesity effect","volume":"19","author":"Srivastava","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41572-018-0001-z","article-title":"Atopic dermatitis","volume":"4","author":"Weidinger","year":"2018","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0091-6749(92)90134-N","article-title":"Increased number of immunoreactive nerve fibers in atopic dermatitis","volume":"90","author":"Tobin","year":"1992","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.jaci.2010.10.028","article-title":"Calcitonin gene-related peptide\u2013 and vascular endothelial growth factor-positive inflammatory cells in late-phase allergic skin reactions in atopic subjects","volume":"127","author":"Kay","year":"2011","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.jaci.2008.12.1110","article-title":"The histamine H4 receptor is functionally expressed on TH2 cells","volume":"123","author":"Gutzmer","year":"2009","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1007\/s12016-020-08802-9","article-title":"Current and Future Monoclonal Antibodies in the Treatment of Atopic Dermatitis","volume":"59","author":"Chun","year":"2020","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(06)68340-2","article-title":"Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: A double-blind, randomised controlled trial","volume":"367","author":"Meggitt","year":"2006","journal-title":"Lancet"},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.jaci.2017.09.033","article-title":"Methotrexate versus azathioprine in patients with atopic dermatitis: 2-year follow-up data","volume":"141","author":"Roekevisch","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1111\/bjd.16240","article-title":"Methotrexate and azathioprine for severe atopic dermatitis: A 5-year follow-up study of a randomized controlled trial","volume":"178","author":"Gerbens","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"5S","DOI":"10.1177\/1203475419857669","article-title":"Evidence Review of Topical Calcineurin Inhibitors for the Treatment of Adult Atopic Dermatitis","volume":"23","author":"Hong","year":"2019","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"e2021145","DOI":"10.5826\/dpc.1104a145","article-title":"Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: Focus on Abrocitinib, Baricitinib, and Upadacitinib","volume":"11","author":"Nogueira","year":"2021","journal-title":"Dermatol. Pract. Concept."},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1080\/14712598.2022.2035356","article-title":"Biological agents targeting interleukin-13 for atopic dermatitis","volume":"22","author":"Chiricozzi","year":"2022","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s13555-021-00678-7","article-title":"Pharmacokinetics, Safety, Efficacy, and Biomarker Profiles During Nemolizumab Treatment of Atopic Dermatitis in Adolescents","volume":"12","author":"Sidbury","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"e2021144","DOI":"10.5826\/dpc.1104a144","article-title":"The New Era of Biologics in Atopic Dermatitis: A Review","volume":"11","author":"Schneider","year":"2021","journal-title":"Dermatol. Pract. Concept."},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.jaad.2016.05.046","article-title":"Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults","volume":"75","author":"Paller","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s13555-021-00646-1","article-title":"Matching-Adjusted Indirect Comparison of Crisaborole Ointment 2% vs. Topical Calcineurin Inhibitors in the Treatment of Patients with Mild-to-Moderate Atopic Dermatitis","volume":"12","author":"Thom","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1001\/jamadermatol.2021.3023","article-title":"Efficacy and Safety of Upadacitinib vs Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial","volume":"157","author":"Blauvelt","year":"2021","journal-title":"JAMA Dermatol."},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s40265-020-01291-2","article-title":"Delgocitinib: First Approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1358\/dot.2021.57.12.3352760","article-title":"Delgocitinib in atopic dermatitis","volume":"57","author":"Ho","year":"2021","journal-title":"Drugs Today"},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"455","DOI":"10.2340\/00015555-1360","article-title":"Relieving the pruritus of atopic dermatitis: A meta-analysis","volume":"92","author":"Sher","year":"2012","journal-title":"Acta Derm. Venereol."},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/exd.12414","article-title":"Cannabinoid 1 receptors in keratinocytes attenuate fluorescein isothiocyanate-induced mouse atopic-like dermatitis","volume":"23","author":"Gaffal","year":"2014","journal-title":"Exp. Dermatol."},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ejphar.2006.05.040","article-title":"The cannabinoid CB2 receptor inverse agonist JTE-907 suppresses spontaneous itch-associated responses of NC mice, a model of atopic dermatitis","volume":"542","author":"Maekawa","year":"2006","journal-title":"Eur. J. Pharmacol."},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.npep.2011.03.005","article-title":"Inhibitory CB1 and activating\/desensitizing TRPV1-mediated cannabinoid actions on CGRP release in rodent skin","volume":"45","author":"Engel","year":"2011","journal-title":"Neuropeptides"},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"22","DOI":"10.5021\/ad.2016.28.1.22","article-title":"Selective Cannabinoid Receptor-1 Agonists Regulate Mast Cell Activation in an Oxazolone-Induced Atopic Dermatitis Model","volume":"28","author":"Nam","year":"2016","journal-title":"Ann. Dermatol."},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"329-e77","DOI":"10.1111\/vde.13077","article-title":"The effect of a mixed cannabidiol and cannabidiolic acid based oil on client-owned dogs with atopic dermatitis","volume":"33","author":"Loewinger","year":"2022","journal-title":"Vet. Dermatol."},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1111\/exd.13704","article-title":"The role of skin barrier in occupational contact dermatitis","volume":"27","author":"Jakasa","year":"2018","journal-title":"Exp. Dermatol."},{"key":"ref_270","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s12016-021-08875-0","article-title":"Contact Dermatitis: Classifications and Management","volume":"61","author":"Li","year":"2021","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jaad.2017.02.001","article-title":"Association between atopic dermatitis and contact sensitization: A systematic review and meta-analysis","volume":"77","author":"Hamann","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_272","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1093\/ije\/22.2.288","article-title":"Prevalence of hand dermatitis in different occupations","volume":"22","author":"Smit","year":"1993","journal-title":"Int. J. Epidemiol."},{"key":"ref_273","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1001\/archderm.140.12.1453","article-title":"Oral alitretinoin (9-cis-retinoic acid) therapy for chronic hand dermatitis in patients refractory to standard therapy: Results of a randomized, double-blind, placebo-controlled, multicenter trial","volume":"140","author":"Ruzicka","year":"2004","journal-title":"Arch. Dermatol."},{"key":"ref_274","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/j.1365-2133.1989.tb08197.x","article-title":"Azathioprine treatment in chronic actinic dermatitis: A double-blind controlled trial with monitoring of exposure to ultraviolet radiation","volume":"121","author":"Murphy","year":"1989","journal-title":"Br. J. Dermatol."},{"key":"ref_275","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/j.1398-9995.2009.02254.x","article-title":"Protective role of palmitoylethanolamide in contact allergic dermatitis","volume":"65","author":"Petrosino","year":"2010","journal-title":"Allergy"},{"key":"ref_276","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1124\/jpet.117.244368","article-title":"Anti-inflammatory Properties of Cannabidiol, a Nonpsychotropic Cannabinoid, in Experimental Allergic Contact Dermatitis","volume":"365","author":"Petrosino","year":"2018","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_277","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.ejphar.2016.10.005","article-title":"Palmitoylethanolamide reduces inflammation and itch in a mouse model of contact allergic dermatitis","volume":"791","author":"Vaia","year":"2016","journal-title":"Eur. J. Pharmacol."},{"key":"ref_278","first-page":"334","article-title":"A nonsteroidal lamellar matrix cream containing palmitoylethanolamide for the treatment of atopic dermatitis","volume":"9","author":"Kircik","year":"2010","journal-title":"J. Drugs Dermatol."},{"key":"ref_279","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ejmech.2018.09.070","article-title":"Synthesis of novel 2-(1-adamantanylcarboxamido)thiophene derivatives. Selective cannabinoid type 2 (CB2) receptor agonists as potential agents for the treatment of skin inflammatory disease","volume":"161","author":"Mugnaini","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_280","first-page":"420","article-title":"In vitro and in vivo pharmacological characterization of JTE-907, a novel selective ligand for cannabinoid CB2 receptor","volume":"296","author":"Iwamura","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_281","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.lfs.2006.09.026","article-title":"Involvement of cannabinoid CB2 receptors in the IgE-mediated triphasic cutaneous reaction in mice","volume":"80","author":"Ueda","year":"2007","journal-title":"Life Sci."},{"key":"ref_282","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ejphar.2005.08.013","article-title":"Involvement of cannabinoid CB2 receptor-mediated response and efficacy of cannabinoid CB2 receptor inverse agonist, JTE-907, in cutaneous inflammation in mice","volume":"520","author":"Ueda","year":"2005","journal-title":"Eur. J. Pharmacol."},{"key":"ref_283","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1046\/j.0022-202x.2001.01626.x","article-title":"Topical peroxisome proliferator activated receptor-\u03b1 activators reduce inflammation in irritant and allergic contact dermatitis models","volume":"118","author":"Sheu","year":"2002","journal-title":"J. Investig. Dermatol."},{"key":"ref_284","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.jid.2017.07.853","article-title":"The N-Acylethanolamine Acid Amidase Inhibitor ARN077 Suppresses Inflammation and Pruritus in a Mouse Model of Allergic Dermatitis","volume":"138","author":"Sasso","year":"2018","journal-title":"J. Investig. Dermatol."},{"key":"ref_285","first-page":"201","article-title":"Topical N-palmitoyl serinol, a commensal bacterial metabolite, prevents the development of epidermal permeability barrier dysfunction in a murine model of atopic dermatitis-like skin","volume":"85","author":"Wen","year":"2021","journal-title":"Can. J. Vet. Res."},{"key":"ref_286","doi-asserted-by":"crossref","first-page":"e14290","DOI":"10.1111\/ijcp.14290","article-title":"An updated guide in the management of psoriasis for every practitioner","volume":"75","author":"Timis","year":"2021","journal-title":"Int. J. Clin. Pract."},{"key":"ref_287","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/1346-8138.14139","article-title":"Pathogenesis of psoriasis and development of treatment","volume":"45","author":"Ogawa","year":"2018","journal-title":"J. Dermatol."},{"key":"ref_288","doi-asserted-by":"crossref","unstructured":"Cheng, P., Liu, T., Zhou, W.-Y., Zhuang, Y., Peng, L., Zhang, J.-Y., Yin, Z.-N., Mao, X., Guo, G., and Shi, Y. (2012). Role of gamma-delta T cells in host response against Staphylococcus aureus-induced pneumonia. BMC Immunol., 13.","DOI":"10.1186\/1471-2172-13-38"},{"key":"ref_289","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1046\/j.1523-1747.1998.00347.x","article-title":"Interleukin-17 and interferon-gamma synergize in the enhancement of proinflammatory cytokine production by human keratinocytes","volume":"111","author":"Teunissen","year":"1998","journal-title":"J. Investig. Dermatol."},{"key":"ref_290","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.jaad.2020.07.087","article-title":"Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures","volume":"84","author":"Elmets","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_291","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1159\/000247698","article-title":"Intermittent corticosteroid maintenance treatment of psoriasis: A double-blind multicenter trial of augmented betamethasone dipropionate ointment in a pulse dose treatment regimen","volume":"183","author":"Katz","year":"1991","journal-title":"Dermatologica"},{"key":"ref_292","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.jaad.2008.12.032","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies","volume":"60","author":"Menter","year":"2009","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_293","doi-asserted-by":"crossref","first-page":"e56991","DOI":"10.7554\/eLife.56991","article-title":"Dithranol targets keratinocytes, their crosstalk with neutrophils and inhibits the IL-36 inflammatory loop in psoriasis","volume":"9","author":"Benezeder","year":"2020","journal-title":"eLife"},{"key":"ref_294","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1067\/mjd.2003.103","article-title":"Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks","volume":"48","author":"Weinstein","year":"2003","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_295","doi-asserted-by":"crossref","first-page":"816757","DOI":"10.3389\/fbioe.2021.816757","article-title":"Acitretin-Conjugated Dextran Nanoparticles Ameliorate Psoriasis-like Skin Disease at Low Dosages","volume":"9","author":"Lan","year":"2021","journal-title":"Front. Bioeng. Biotechnol."},{"key":"ref_296","doi-asserted-by":"crossref","first-page":"e12453","DOI":"10.1111\/dth.12453","article-title":"Optimizing acitretin use in patients with plaque psoriasis","volume":"30","author":"Chiricozzi","year":"2017","journal-title":"Dermatol. Ther."},{"key":"ref_297","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1111\/bjd.14676","article-title":"Oral fumaric acid esters for psoriasis: Abridged Cochrane systematic review including GRADE assessments","volume":"175","author":"Atwan","year":"2016","journal-title":"Br. J. Dermatol."},{"key":"ref_298","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/idoj.IDOJ_437_18","article-title":"Apremilast in Psoriasis and Beyond: Big Hopes on a Small Molecule","volume":"10","author":"Afra","year":"2019","journal-title":"Indian Dermatol. Online J."},{"key":"ref_299","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S0140-6736(14)62113-9","article-title":"Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: A phase 3 randomised non-inferiority trial","volume":"386","author":"Bachelez","year":"2015","journal-title":"Lancet"},{"key":"ref_300","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/j.jaad.2020.02.044","article-title":"Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies","volume":"82","author":"Menter","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_301","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1111\/j.1468-3083.2010.03667.x","article-title":"Efficacy and safety of mycophenolate mofetil vs. methotrexate for the treatment of chronic plaque psoriasis","volume":"24","author":"Akhyani","year":"2010","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_302","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s13555-021-00511-1","article-title":"Comparative Efficacy and Relative Ranking of Biologics and Oral Therapies for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis","volume":"11","author":"Armstrong","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_303","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jid.2019.07.679","article-title":"A Phase IV, Randomized, Double-Blind, Placebo-Controlled Crossover Study of the Effects of Ustekinumab on Vascular Inflammation in Psoriasis (the VIP-U Trial)","volume":"140","author":"Gelfand","year":"2020","journal-title":"J. Investig. Dermatol."},{"key":"ref_304","doi-asserted-by":"crossref","first-page":"212594","DOI":"10.7573\/dic.212594","article-title":"Guselkumab for the treatment of psoriasis\u2014Evidence to date","volume":"8","author":"Nogueira","year":"2019","journal-title":"Drugs Context"},{"key":"ref_305","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1159\/000519924","article-title":"Effective and Safe Treatment of Psoriatic Disease with the Anti-IL-23p19 Biologic Tildrakizumab: Results of a Real-World Prospective Cohort Study in Nonselected Patients","volume":"238","author":"Drerup","year":"2021","journal-title":"Dermatology"},{"key":"ref_306","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1111\/jdv.18010","article-title":"Long-term, durable, absolute Psoriasis Area and Severity Index and health-related quality of life improvements with risankizumab treatment: A post hoc integrated analysis of patients with moderate-to-severe plaque psoriasis","volume":"36","author":"Gooderham","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_307","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.2147\/DDDT.S92128","article-title":"Spotlight on ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Design, development, and use in therapy","volume":"11","author":"Giunta","year":"2017","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_308","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1002\/jcph.876","article-title":"Population Pharmacokinetic Modeling of Secukinumab in Patients with Moderate to Severe Psoriasis","volume":"57","author":"Bruin","year":"2017","journal-title":"J. Clin. Pharmacol."},{"key":"ref_309","doi-asserted-by":"crossref","first-page":"212570","DOI":"10.7573\/dic.212570","article-title":"Brodalumab in psoriasis: Evidence to date and clinical potential","volume":"8","author":"Foulkes","year":"2019","journal-title":"Drugs Context"},{"key":"ref_310","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ejps.2010.06.004","article-title":"In vitro metabolism of indomethacin morpholinylamide (BML-190), an inverse agonist for the peripheral cannabinoid receptor (CB2) in rat liver microsomes","volume":"41","author":"Zhang","year":"2010","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_311","doi-asserted-by":"crossref","first-page":"e02264-19","DOI":"10.1128\/mBio.02264-19","article-title":"The Aminoalkylindole BML-190 Negatively Regulates Chitosan Synthesis via the Cyclic AMP\/Protein Kinase A1 Pathway in Cryptococcus neoformans","volume":"10","author":"Maybruck","year":"2019","journal-title":"mBio"},{"key":"ref_312","doi-asserted-by":"crossref","unstructured":"Urasaki, Y., Beaumont, C., Workman, M., Talbot, J.N., Hill, D.K., and Le, T.T. (2020). Fast-Acting and Receptor-Mediated Regulation of Neuronal Signaling Pathways by Copaiba Essential Oil. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21072259"},{"key":"ref_313","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1038\/jid.2010.421","article-title":"Endocannabinoids modulate human epidermal keratinocyte proliferation and survival via the sequential engagement of cannabinoid receptor-1 and transient receptor potential vanilloid-1","volume":"131","author":"Dobrosi","year":"2011","journal-title":"J. Investig. Dermatol."},{"key":"ref_314","doi-asserted-by":"crossref","first-page":"3545","DOI":"10.4049\/jimmunol.1500546","article-title":"Anandamide Suppresses Proinflammatory T Cell Responses In Vitro through Type-1 Cannabinoid Receptor-Mediated mTOR Inhibition in Human Keratinocytes","volume":"197","author":"Rapino","year":"2016","journal-title":"J. Immunol."},{"key":"ref_315","doi-asserted-by":"crossref","unstructured":"\u0141uczaj, W., Dobrzy\u0144ska, I., Wro\u0144ski, A., Domingues, M.R., Domingues, P., and Skrzydlewska, E. (2020). Cannabidiol-Mediated Changes to the Phospholipid Profile of UVB-Irradiated Keratinocytes from Psoriatic Patients. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21186592"},{"key":"ref_316","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/j.1610-0387.2007.06274.x","article-title":"Pathophysiology of acne","volume":"5","author":"Degitz","year":"2007","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"ref_317","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1016\/S0140-6736(12)61729-2","article-title":"Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990\u20132010: A systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Vos","year":"2012","journal-title":"Lancet"},{"key":"ref_318","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJMcp1702493","article-title":"Acne Vulgaris","volume":"379","author":"Zaenglein","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_319","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s40257-018-00417-3","article-title":"Acne, the Skin Microbiome, and Antibiotic Treatment","volume":"20","author":"Xu","year":"2019","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_320","unstructured":"Sutaria, A.H., Masood, S., and Schlessinger, J. (2022). Acne Vulgaris, StatPearls Publishing."},{"key":"ref_321","doi-asserted-by":"crossref","unstructured":"Heng, A.H.S., Say, Y.-H., Sio, Y.Y., Ng, Y.T., and Chew, F.T. (2021). Gene variants associated with acne vulgaris presentation and severity: A systematic review and meta-analysis. BMC Med. Genom., 14.","DOI":"10.1186\/s12920-021-00953-8"},{"key":"ref_322","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/1346-8138.14314","article-title":"Optimizing the use of topical retinoids in Asian acne patients","volume":"45","author":"See","year":"2018","journal-title":"J. Dermatol."},{"key":"ref_323","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/j.1365-2133.1988.tb03474.x","article-title":"Inhibition of 5 alpha-reductase activity in human skin by zinc and azelaic acid","volume":"119","author":"Stamatiadis","year":"1988","journal-title":"Br. J. Dermatol."},{"key":"ref_324","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000354888","article-title":"Azelaic acid: Properties and mode of action","volume":"27","author":"Sieber","year":"2014","journal-title":"Skin Pharmacol. Physiol."},{"key":"ref_325","first-page":"CD011368","article-title":"Topical azelaic acid, salicylic acid, nicotinamide, sulphur, zinc and fruit acid (alpha-hydroxy acid) for acne","volume":"5","author":"Liu","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_326","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1111\/exd.13934","article-title":"Salicylic acid treats acne vulgaris by suppressing AMPK\/SREBP1 pathway in sebocytes","volume":"28","author":"Lu","year":"2019","journal-title":"Exp. Dermatol."},{"key":"ref_327","doi-asserted-by":"crossref","first-page":"611","DOI":"10.21037\/apm-21-3935","article-title":"Efficacy and safety of dapsone gel for acne: A systematic review and meta-analysis","volume":"11","author":"Wang","year":"2022","journal-title":"Ann. Palliat. Med."},{"key":"ref_328","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1093\/neuonc\/noaa026","article-title":"Hemolytic anemia associated with dapsone PCP prophylaxis in GBM patients with normal G6PD activity","volume":"22","author":"Rogers","year":"2020","journal-title":"Neuro Oncol."},{"key":"ref_329","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/ijd.12942","article-title":"Making sense of the effects of the cumulative dose of isotretinoin in acne vulgaris","volume":"55","author":"Rademaker","year":"2016","journal-title":"Int. J. Dermatol."},{"key":"ref_330","first-page":"CD004425","article-title":"Combined oral contraceptive pills for treatment of acne","volume":"6","author":"Arowojolu","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_331","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s13555-020-00481-w","article-title":"New Acne Therapies and Updates on Use of Spironolactone and Isotretinoin: A Narrative Review","volume":"11","author":"Han","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_332","doi-asserted-by":"crossref","first-page":"3713","DOI":"10.1172\/JCI64628","article-title":"Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes","volume":"124","author":"Sugawara","year":"2014","journal-title":"J. Clin. Investig."},{"key":"ref_333","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/exd.13042","article-title":"Differential effectiveness of selected non-psychotropic phytocannabinoids on human sebocyte functions implicates their introduction in dry\/seborrhoeic skin and acne treatment","volume":"25","author":"Markovics","year":"2016","journal-title":"Exp. Dermatol."},{"key":"ref_334","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.fitote.2010.04.009","article-title":"Comparative topical anti-inflammatory activity of cannabinoids and cannabivarins","volume":"81","author":"Tubaro","year":"2010","journal-title":"Fitoterapia"},{"key":"ref_335","doi-asserted-by":"crossref","unstructured":"Jin, S., and Lee, M.-Y. (2018). The ameliorative effect of hemp seed hexane extracts on the Propionibacterium acnes-induced inflammation and lipogenesis in sebocytes. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0202933"},{"key":"ref_336","doi-asserted-by":"crossref","first-page":"4573","DOI":"10.2147\/JIR.S374692","article-title":"Cannabidiol Inhibits Inflammation Induced by Cutibacterium acnes-Derived Extracellular Vesicles via Activation of CB2 Receptor in Keratinocytes","volume":"15","author":"Jiang","year":"2022","journal-title":"J. Inflamm. Res."},{"key":"ref_337","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s42003-020-01530-y","article-title":"The antimicrobial potential of cannabidiol","volume":"4","author":"Blaskovich","year":"2021","journal-title":"Commun. Biol."},{"key":"ref_338","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet"},{"key":"ref_339","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s11926-017-0630-3","article-title":"Innate Immunity in Systemic Sclerosis","volume":"19","author":"Dowson","year":"2017","journal-title":"Curr. Rheumatol. Rep."},{"key":"ref_340","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3892\/etm.2021.11057","article-title":"Old and new therapeutic strategies in systemic sclerosis (Review)","volume":"23","author":"Bobeica","year":"2022","journal-title":"Exp. Ther. Med."},{"key":"ref_341","doi-asserted-by":"crossref","first-page":"55","DOI":"10.7861\/clinmedicine.16-1-55","article-title":"Advances in pathogenesis and treatment of systemic sclerosis","volume":"16","author":"Denton","year":"2016","journal-title":"Clin. Med."},{"key":"ref_342","first-page":"3","article-title":"One year in review 2019: Systemic sclerosis","volume":"37","author":"Barsotti","year":"2019","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_343","doi-asserted-by":"crossref","first-page":"4774","DOI":"10.1158\/0008-5472.CAN-07-6307","article-title":"BIBF 1120: Triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy","volume":"68","author":"Hilberg","year":"2008","journal-title":"Cancer Res."},{"key":"ref_344","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13075-020-2141-2","article-title":"ACE inhibitors in SSc patients display a risk factor for scleroderma renal crisis-a EUSTAR analysis","volume":"22","author":"Varisco","year":"2020","journal-title":"Arthritis Res. Ther."},{"key":"ref_345","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/ijd.15388","article-title":"Pharmacological activation of PPAR-\u03b3: A potential therapy for skin fibrosis","volume":"60","author":"Ghosh","year":"2021","journal-title":"Int. J. Dermatol."},{"key":"ref_346","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/978-1-4939-7113-8_2","article-title":"The Bleomycin Model of Pulmonary Fibrosis","volume":"1627","author":"Liu","year":"2017","journal-title":"Methods Mol. Biol."},{"key":"ref_347","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2353\/ajpath.2010.090763","article-title":"Targeting the cannabinoid pathway limits the development of fibrosis and autoimmunity in a mouse model of systemic sclerosis","volume":"177","author":"Servettaz","year":"2010","journal-title":"Am. J. Pathol."},{"key":"ref_348","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1136\/ard.2010.137539","article-title":"The cannabinoid WIN55, 212\u20132 abrogates dermal fibrosis in scleroderma bleomycin model","volume":"70","author":"Balistreri","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"ref_349","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1002\/art.24395","article-title":"The cannabinoid receptor CB2 exerts antifibrotic effects in experimental dermal fibrosis","volume":"60","author":"Akhmetshina","year":"2009","journal-title":"Arthritis Rheum."},{"key":"ref_350","doi-asserted-by":"crossref","first-page":"112007","DOI":"10.1016\/j.biopha.2021.112007","article-title":"EHP-101 alleviates angiotensin II-induced fibrosis and inflammation in mice","volume":"142","author":"Navarrete","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"ref_351","doi-asserted-by":"crossref","first-page":"153160","DOI":"10.1016\/j.phymed.2019.153160","article-title":"Celastrol is a novel selective agonist of cannabinoid receptor 2 with anti-inflammatory and anti-fibrotic activity in a mouse model of systemic sclerosis","volume":"67","author":"Jiang","year":"2020","journal-title":"Phytomedicine"},{"key":"ref_352","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1093\/rheumatology\/kep189","article-title":"Cannabinoids inhibit fibrogenesis in diffuse systemic sclerosis fibroblasts","volume":"48","author":"Selvi","year":"2009","journal-title":"Rheumatology"},{"key":"ref_353","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1002\/art.24761","article-title":"Loss of peroxisome proliferator-activated receptor gamma in mouse fibroblasts results in increased susceptibility to bleomycin-induced skin fibrosis","volume":"60","author":"Kapoor","year":"2009","journal-title":"Arthritis Rheum."},{"key":"ref_354","doi-asserted-by":"crossref","first-page":"e471","DOI":"10.1002\/ctm2.471","article-title":"CB1 R and iNOS are distinct players promoting pulmonary fibrosis in Hermansky-Pudlak syndrome","volume":"11","author":"Cinar","year":"2021","journal-title":"Clin. Transl. Med."},{"key":"ref_355","doi-asserted-by":"crossref","first-page":"e92281","DOI":"10.1172\/jci.insight.92281","article-title":"Cannabinoid CB1 receptor overactivity contributes to the pathogenesis of idiopathic pulmonary fibrosis","volume":"2","author":"Cinar","year":"2017","journal-title":"JCI Insight"},{"key":"ref_356","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1165\/rcmb.2014-0331OC","article-title":"Protection from Radiation-Induced Pulmonary Fibrosis by Peripheral Targeting of Cannabinoid Receptor-1","volume":"53","author":"Bronova","year":"2015","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"ref_357","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1136\/annrheumdis-2012-201823","article-title":"Inactivation of fatty acid amide hydrolase exacerbates experimental fibrosis by enhanced endocannabinoid-mediated activation of CB1","volume":"71","author":"Horn","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"ref_358","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1002\/art.27642","article-title":"Inactivation of the cannabinoid receptor CB1 prevents leukocyte infiltration and experimental fibrosis","volume":"62","author":"Marquart","year":"2010","journal-title":"Arthritis Rheum."},{"key":"ref_359","doi-asserted-by":"crossref","first-page":"1179547619855370","DOI":"10.1177\/1179547619855370","article-title":"Dermatomyositis: An Acute Flare and Current Treatments","volume":"12","author":"Okogbaa","year":"2019","journal-title":"Clin. Med. Insights Case Rep."},{"key":"ref_360","doi-asserted-by":"crossref","unstructured":"Fujisawa, T. (2021). Management of Myositis-Associated Interstitial Lung Disease. Medicina, 57.","DOI":"10.3390\/medicina57040347"},{"key":"ref_361","doi-asserted-by":"crossref","unstructured":"Dressler, F., and Maurer, B. (Z. Rheumatol., 2022). Dermatomyositis und juvenile Dermatomyositis, Z. Rheumatol., epub ahead of print.","DOI":"10.1007\/s00393-022-01205-5"},{"key":"ref_362","first-page":"e14942","article-title":"Treatment challenges in clinically amyopathic dermatomyositis: A case series and review of new therapeutic options for skin involvement","volume":"34","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_363","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1016\/j.jid.2017.05.035","article-title":"Cannabinoid Reduces Inflammatory Cytokines, Tumor Necrosis Factor-\u03b1, and Type I Interferons in Dermatomyositis In Vitro","volume":"137","author":"Robinson","year":"2017","journal-title":"J. Investig. Dermatol."},{"key":"ref_364","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/bjd.16498","article-title":"Itch in dermatomyositis: The role of increased skin interleukin-31","volume":"179","author":"Kim","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_365","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1038\/jid.2011.169","article-title":"Development of allele-specific therapeutic siRNA for keratin 5 mutations in epidermolysis bullosa simplex","volume":"131","author":"Atkinson","year":"2011","journal-title":"J. Investig. Dermatol."},{"key":"ref_366","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1111\/jdv.17012","article-title":"Novel insights into the epidemiology of epidermolysis bullosa (EB) from the Dutch EB Registry: EB more common than previously assumed?","volume":"35","author":"Baardman","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_367","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s40257-021-00626-3","article-title":"Investigational Treatments for Epidermolysis Bullosa","volume":"22","author":"Hou","year":"2021","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_368","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1038\/jid.2013.31","article-title":"The pathogenetic role of IL-1\u03b2 in severe epidermolysis bullosa simplex","volume":"133","author":"Wally","year":"2013","journal-title":"J. Investig. Dermatol."},{"key":"ref_369","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/bjd.16897","article-title":"Epidermolysis bullosa simplex generalized severe induces a T helper 17 response and is improved by apremilast treatment","volume":"180","author":"Castela","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_370","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1111\/bjd.18855","article-title":"Treatment of epidermolysis bullosa pruriginosa-associated pruritus with dupilumab","volume":"182","author":"Shehadeh","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_371","doi-asserted-by":"crossref","first-page":"551","DOI":"10.25259\/IJDVL_71_2021","article-title":"Purified oral cannabidiol for pain management in severe recessive dystrophic epidermolysis bullosa","volume":"88","author":"Welponer","year":"2022","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"key":"ref_372","unstructured":"U.S. National Library of Medicine, ClinicalTrials.gov (2022, June 15). The Efficacy and Safety of 3% Cannabidiol (CBD) Cream in Patients with Epidermolysis Bullosa: A Phase II\/III Trial, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04613102?term=CBD&cond=Skin+Diseases&draw=1&rank=6."},{"key":"ref_373","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/bjd.17619","article-title":"Time to drop the stigma: Cannabinoids are drugs that may alleviate pain in people with epidermolysis bullosa","volume":"180","author":"Martinez","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_374","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1111\/bjd.13493","article-title":"The genetics of pyoderma gangrenosum and implications for treatment: A systematic review","volume":"172","author":"DeFilippis","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"ref_375","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s40257-017-0251-7","article-title":"Pyoderma Gangrenosum: An Update on Pathophysiology, Diagnosis and Treatment","volume":"18","author":"Alavi","year":"2017","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_376","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/wrr.12496","article-title":"Relationship between opioid treatment and rate of healing in chronic wounds","volume":"25","author":"Shanmugam","year":"2017","journal-title":"Wound Repair Regen."},{"key":"ref_377","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1159\/000210960","article-title":"Mouse skin inflammation induced by multiple topical applications of 12-O-tetradecanoylphorbol-13-acetate","volume":"4","author":"Stanley","year":"1991","journal-title":"Skin Pharmacol."},{"key":"ref_378","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1111\/jphp.12082","article-title":"Structure-dependent inhibitory effects of synthetic cannabinoids against 12-O-tetradecanoylphorbol-13-acetate-induced inflammation and skin tumour promotion in mice","volume":"65","author":"Nakajima","year":"2013","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_379","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/DER.0000000000000722","article-title":"Anti-inflammatory Effect of Cannabidiol and Palmitoylethanolamide Containing Topical Formulation on Skin in a 12-O-Tetradecanoylphorbol-13-Acetate-Induced Dermatitis Model in Mice","volume":"33","author":"Rundle","year":"2021","journal-title":"Dermatitis"},{"key":"ref_380","doi-asserted-by":"crossref","unstructured":"Capozzi, A., Caissutti, D., Mattei, V., Gado, F., Martellucci, S., Longo, A., Recalchi, S., Manganelli, V., Riitano, G., and Garofalo, T. (2021). Anti-Inflammatory Activity of a CB2 Selective Cannabinoid Receptor Agonist: Signaling and Cytokines Release in Blood Mononuclear Cells. Molecules, 27.","DOI":"10.3390\/molecules27010064"},{"key":"ref_381","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1087-0024.2005.10204.x","article-title":"The genetic basis of pachyonychia congenita","volume":"10","author":"Smith","year":"2005","journal-title":"J. Investig. Dermatol. Symp. Proc."},{"key":"ref_382","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.2353\/ajpath.2010.100454","article-title":"The pathogenesis of primary cicatricial alopecias","volume":"177","author":"Harries","year":"2010","journal-title":"Am. J. Pathol."},{"key":"ref_383","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1111\/bjd.16570","article-title":"Cover Image: Neuroendocrine treatment of inherited keratin disorders by cannabinoids?","volume":"178","author":"Ramot","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_384","first-page":"e93","article-title":"A therapeutic effect of cbd-enriched ointment in inflammatory skin diseases and cutaneous scars","volume":"170","author":"Palmieri","year":"2019","journal-title":"Clin. Ter."},{"key":"ref_385","doi-asserted-by":"crossref","first-page":"e2123930","DOI":"10.1001\/jamanetworkopen.2021.23930","article-title":"Safety and Tolerability of Transdermal Cannabidiol Gel in Children with Developmental and Epileptic Encephalopathies: A Nonrandomized Controlled Trial","volume":"4","author":"Scheffer","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_386","unstructured":"U.S. National Library of Medicine, ClinicalTrials.gov (2022, June 15). The Pharmacokinetics and Pharmacodynamics of Hemp-based Topical Cannabinoid Products. ClinicalTrials.gov Identifier: NCT04741477, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04741477?term=cannabinoid&draw=4&rank=7."},{"key":"ref_387","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.2147\/JIR.S355489","article-title":"The Anti-Inflammatory Effects of Cannabidiol (CBD) on Acne","volume":"15","author":"Peyravian","year":"2022","journal-title":"J. Inflamm. Res."},{"key":"ref_388","doi-asserted-by":"crossref","first-page":"S180","DOI":"10.1016\/j.jid.2018.03.1074","article-title":"1061 The safety of topical cannabidiol (CBD) for the treatment of acne","volume":"138","author":"Spleman","year":"2018","journal-title":"J. Investig. Dermatol."},{"key":"ref_389","unstructured":"U.S. National Library of Medicine, ClinicalTrials.gov (2022, June 15). Evaluation of BTX 1503 in Patients with Moderate to Severe Acne Vulgaris\u201d. ClinicalTrials.gov Identifier: NCT03573518, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03573518?term=CBD&cond=Skin+Diseases&draw=1&rank=10."},{"key":"ref_390","first-page":"1389","article-title":"The safety and efficacy of 3% Cannabis seeds extract cream for reduction of human cheek skin sebum and erythema content","volume":"28","author":"Ali","year":"2015","journal-title":"Pak. J. Pharm. Sci."},{"key":"ref_391","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/j.1600-0625.2009.00890.x","article-title":"New developments in our understanding of acne pathogenesis and treatment","volume":"18","author":"Kurokawa","year":"2009","journal-title":"Exp. Dermatol."},{"key":"ref_392","doi-asserted-by":"crossref","first-page":"S150","DOI":"10.1067\/mjd.2001.113717","article-title":"Uses and complications of isotretinoin therapy","volume":"45","author":"Ellis","year":"2001","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_393","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.clindermatol.2009.03.005","article-title":"The role of isotretinoin in acne therapy: Why not as first-line therapy? facts and controversies","volume":"28","author":"Rigopoulos","year":"2010","journal-title":"Clin. Dermatol."},{"key":"ref_394","doi-asserted-by":"crossref","first-page":"53","DOI":"10.26828\/cannabis\/2021.01.003","article-title":"Hair Regrowth with Cannabidiol (CBD)-rich Hemp Extract\u2014A Case Series","volume":"4","author":"Smith","year":"2021","journal-title":"Cannabis"},{"key":"ref_395","unstructured":"U.S. National Library of Medicine, ClinicalTrials.gov (2022, June 15). Androgenetic Alopecia Treatment Using Varin and Cannabidiol Rich Topical Hemp Oil: A Case Series (Hair Regrowth). ClinicalTrials.gov Identifier: NCT04842383, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT04842383."},{"key":"ref_396","first-page":"51","article-title":"Alopecia Areata Treatment with Extracted Cannabis Oil: Case Study 52-year-old Asian Male","volume":"2","author":"Buranakarn","year":"2019","journal-title":"Int. Jounal Sci. Innov. Technol."},{"key":"ref_397","unstructured":"Specht, S., and Persaud, Y. (2022). Asteatotic Eczema, StatPearls Publishing."},{"key":"ref_398","first-page":"277","article-title":"Dermatological Complaints of the Elderly Attending a Dermatology Outpatient Clinic in Turkey: A Prospective Study over a One-year Period","volume":"23","author":"Polat","year":"2015","journal-title":"Acta Dermatovenerol. Croat."},{"key":"ref_399","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/j.1468-3083.2006.01879.x","article-title":"Pimecrolimus cream 1% is effective in asteatotic eczema: Results of a randomized, double-blind, vehicle-controlled study in 40 patients","volume":"21","author":"Schulz","year":"2007","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_400","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.2147\/CIA.S65448","article-title":"N-palmitoylethanolamine and N-acetylethanolamine are effective in asteatotic eczema: Results of a randomized, double-blind, controlled study in 60 patients","volume":"9","author":"Yuan","year":"2014","journal-title":"Clin. Interv. Aging"},{"key":"ref_401","first-page":"80","article-title":"Topical adelmidrol 2% emulsion, a novel aliamide, in the treatment of mild atopic dermatitis in pediatric subjects: A pilot study","volume":"15","author":"Pulvirenti","year":"2007","journal-title":"Acta Dermatovenerol. Croat."},{"key":"ref_402","unstructured":"(2022, June 15). Reuters. Available online: https:\/\/www.reuters.com\/article\/brief-botanix-pharmaceuticals-says-btx-1-idUSFWN2BH1HT."},{"key":"ref_403","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.36849\/JDD.2020.5464","article-title":"An Observational Study of the Application of a Topical Cannabinoid Gel on Sensitive Dry Skin","volume":"19","author":"Maghfour","year":"2020","journal-title":"J. Drugs Dermatol."},{"key":"ref_404","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1080\/09546630510035832","article-title":"Efficacy of dietary hempseed oil in patients with atopic dermatitis","volume":"16","author":"Callaway","year":"2005","journal-title":"J. Dermatolog. Treat."},{"key":"ref_405","unstructured":"U.S. National Library of Medicine, ClinicalTrials.gov (2022, June 15). A Phase Ib\/IIa, Double-Blind, Randomized Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of S-777469 in Subjects with Atopic Dermatitis. ClinicalTrials.gov Identifier: NCT00697710, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00697710?term=cannabinoid&cond=skin&draw=1&rank=6."},{"key":"ref_406","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1468-3083.2007.02351.x","article-title":"Adjuvant treatment of atopic eczema: Assessment of an emollient containing N-palmitoylethanolamine (ATOPA study)","volume":"22","author":"Eberlein","year":"2008","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_407","unstructured":"U.S. National Library of Medicine, ClinicalTrials.gov (2022, June 15). The Effectiveness of a Topical Palmitoylethanolamide (PEA) Formulation (Levagen+) for Reducing Symptoms of Eczema. ClinicalTrials.gov Identifier: NCT05003453, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05003453?term=palmitoylethanolamide&draw=2&rank=7."},{"key":"ref_408","unstructured":"U.S. National Library of Medicine, ClinicalTrials.gov (2022, June 15). Safety, Tolerability, and Efficacy of JBT-101 in Subjects with Dermatomyositis. ClinicalTrials.gov Identifier: NCT02466243, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02466243?term=lenabasum&draw=1&rank=5."},{"key":"ref_409","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1016\/j.jid.2022.03.029","article-title":"Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: A Randomized Clinical Trial","volume":"142","author":"Werth","year":"2022","journal-title":"J. Investig. Dermatol."},{"key":"ref_410","unstructured":"U.S. National Library of Medicine, ClinicalTrials.gov (2022, June 15). A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis (DETERMINE). ClinicalTrials.gov Identifier: NCT03813160, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03813160?cond=Dermatomyositis&draw=2&rank=6."},{"key":"ref_411","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1136\/annrheumdis-2022-eular.5037","article-title":"OP0162 EFFICACY AND SAFETY OF LENABASUM IN THE PHASE 3 DETERMINE TRIAL IN DERMATOMYOSITIS","volume":"81","author":"Werth","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_412","doi-asserted-by":"crossref","first-page":"20406223211055920","DOI":"10.1177\/20406223211055920","article-title":"New perspectives on the treatment of hidradenitis suppurativa","volume":"12","author":"Vilarrasa","year":"2021","journal-title":"Ther. Adv. Chronic Dis."},{"key":"ref_413","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1111\/bjd.17537","article-title":"British Association of Dermatologists guidelines for the management of hidradenitis suppurativa (acne inversa) 2018","volume":"180","author":"Ingram","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_414","unstructured":"U.S. National Library of Medicine (2022, June 15). Study to Investigate the Efficacy and Safety of Cannabis Oil for the Treatment of Subjects with Hidradenitis Suppurativa. ClinicalTrials.gov Identifer: NCT03929835, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03929835."},{"key":"ref_415","doi-asserted-by":"crossref","first-page":"13030","DOI":"10.5070\/D3207023131","article-title":"Topical treatments of skin pain: A general review with a focus on hidradenitis suppurativa with topical agents","volume":"20","author":"Scheinfeld","year":"2014","journal-title":"Dermatol. Online J."},{"key":"ref_416","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s00011-003-1162-z","article-title":"Histamine induced responses are attenuated by a cannabinoid receptor agonist in human skin","volume":"52","author":"Dvorak","year":"2003","journal-title":"Inflamm. Res."},{"key":"ref_417","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1111\/j.1610-0387.2006.06009.x","article-title":"Zoster-associated neuralgias","volume":"4","author":"Wassilew","year":"2006","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"ref_418","first-page":"88","article-title":"Adjuvant topical therapy with a cannabinoid receptor agonist in facial postherpetic neuralgia","volume":"8","author":"Phan","year":"2010","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"ref_419","doi-asserted-by":"crossref","first-page":"639","DOI":"10.2340\/00015555-2593","article-title":"Efficacy of Body Lotion Containing N-palmitoylethanolamine in Subjects with Chronic Pruritus due to Dry Skin: A Dermatocosmetic Study","volume":"97","author":"Visse","year":"2017","journal-title":"Acta Derm. Venereol."},{"key":"ref_420","first-page":"97","article-title":"Efficacy and tolerance of the cream containing structured physiological lipids with endocannabinoids in the treatment of uremic pruritus: A preliminary study","volume":"13","author":"Szepietowski","year":"2005","journal-title":"Acta Dermatovenerol. Croat."},{"key":"ref_421","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1097\/j.pain.0000000000002466","article-title":"Cannabidiol treatment in hand osteoarthritis and psoriatic arthritis: A randomized, double-blind, placebo-controlled trial","volume":"163","author":"Vela","year":"2022","journal-title":"Pain"},{"key":"ref_422","doi-asserted-by":"crossref","first-page":"795","DOI":"10.36849\/JDD.2020.5229","article-title":"Topical Cannabinoids for the Management of Psoriasis Vulgaris: Report of a Case and Review of the Literature","volume":"19","author":"Friedman","year":"2020","journal-title":"J. Drugs Dermatol."},{"key":"ref_423","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1159\/000510896","article-title":"Efficacy and Tolerability of a Shampoo Containing Broad-Spectrum Cannabidiol in the Treatment of Scalp Inflammation in Patients with Mild to Moderate Scalp Psoriasis or Seborrheic Dermatitis","volume":"6","author":"Vincenzi","year":"2020","journal-title":"Skin Appendage Disord."},{"key":"ref_424","unstructured":"U.S. National Library of Medicine, ClinicalTrials.gov (2022, June 15). Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis (RESOLVE-1). ClinicalTrials.gov Identifier: NCT03398837, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03398837?term=cannabinoid&cond=skin&draw=1&rank=8."},{"key":"ref_425","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1002\/art.41294","article-title":"Safety and Efficacy of Lenabasum in a Phase II, Randomized, Placebo-Controlled Trial in Adults with Systemic Sclerosis","volume":"72","author":"Spiera","year":"2020","journal-title":"Arthritis Rheumatol."},{"key":"ref_426","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1002\/art.41302","article-title":"Lenabasum for Skin Disease in Patients with Diffuse Cutaneous Systemic Sclerosis","volume":"72","author":"Hinchcliff","year":"2020","journal-title":"Arthritis Rheumatol."},{"key":"ref_427","unstructured":"U.S. National Library of Medicine, ClinicalTrials.gov (2022, June 15). Study to Evaluate the Safety, Tolerability and Efficacy of Cannabidiol (CBD) as a Steroid-sparing Therapy in Chronic Spontaneous Urticaria (CSU) Patients. ClinicalTrials.gov Identifier: NCT04439955, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04439955?term=CBD&cond=Skin+Diseases&draw=1&rank=4."},{"key":"ref_428","doi-asserted-by":"crossref","unstructured":"Mallard, A., Briskey, D., Richards, A., Mills, D., and Rao, A. (2020). The Effect of Orally Dosed Levagen+\u2122 (palmitoylethanolamide) on Exercise Recovery in Healthy Males-A Double-Blind, Randomized, Placebo-Controlled Study. Nutrients, 12.","DOI":"10.3390\/nu12030596"},{"key":"ref_429","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/sleep\/zsab234","article-title":"Medical cannabis and cannabinoids for impaired sleep: A systematic review and meta-analysis of randomized clinical trials","volume":"45","author":"AminiLari","year":"2022","journal-title":"Sleep"},{"key":"ref_430","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s42238-021-00061-5","article-title":"Reasons for cannabidiol use: A cross-sectional study of CBD users, focusing on self-perceived stress, anxiety, and sleep problems","volume":"3","author":"Moltke","year":"2021","journal-title":"J. Cannabis Res."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/11\/24\/4102\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:43:08Z","timestamp":1760146988000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/11\/24\/4102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,16]]},"references-count":430,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["cells11244102"],"URL":"https:\/\/doi.org\/10.3390\/cells11244102","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,16]]}}}